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Abbreviations
AGID agar gel immunodiffusion
BHV bovine herpes virus
BLV bovine leukosis virus
BTM bulk-tank milk
BVD bovine viral diarrhoea, also BVD / MD
BVDV bovine viral diarrhoea virus
CAEV caprine arthritis encephalitis virus
CNS central nervous system
cp cytopathic form of BVD virus 
CPE cytopathic effect
DNA deoxyribonucleic acid
Decision (in context of EU legislation) Decision of the Commission of 
  the European community
Directive (in context of EU legislation) Directive of the Council of European 
  community
EBL enzootic bovine leukosis
EIA enzyme immunoassay
ELISA enzyme-linked immunosorbent assay
IACS Integrated Administration and Control System (EU-implemented)
IBR infectious bovine rhinotracheitis, also IBR / IPV
ID 50 infectious dose for half (50%) of target population
IgM immunoglobulin of type M
IPV infectious pustular vulvovaginitis
LD 50 lethal dose for half (50%) of target population
LR latency-related
LSA lymphosarcoma
MD mucosal disease
MV maedi–visna of sheep
MVV maedi–visna virus
ncp noncytopathic form of BVD virus 
PCR polymerase chain reaction
PI persistently infected, used especially in reference to BVD
PL persistent lymphocytosis
RNA ribonucleic acid
RT reverse transcriptase
se sensitivity of a diagnostic test
SIR model Susceptible–Infective–Recovered compartmental model
SN serum neutralization, alternative (inexact) abbreviation for VN
sp specifi city of a diagnostic test
SRLV small ruminant lentivirus
VN virus neutralization test
7Definitions
Basic reproduction ratio, R 0 : the number of secondary cases generated by one pri-
mary case in a totally susceptible population of defi ned density. 
Explant culture: tissue transferred from the body and placed in a culture medium 
for growth.
Heuristic: relating to or using a general formulation that serves to guide investiga-
tion, or pertaining to the use of the general knowledge gained by experience.
From Putt et al. (1988):
Infectivity is the measure of the ability of the disease agent to establish itself 
in the host. The term can be used qualitatively (e.g. low, medium or high), or 
it can be quantifi ed using a statistic like infectious dose 50, or ID 50. This refers 
to the individual dose or numbers of the agent required to infect half (50%) 
of a specifi ed population in controlled conditions. It often is expensive or not 
feasible to determine the actual ID 50 and the infectivity is expressed using the 
tissue culture ID 50 or TCID 50 as the dimension. Another gauge for infectivity 
could be the within-herd basic reproduction ratio.
Virulence is a measure of the severity of the disease caused by the agent. In a 
strict sense it is a laboratory term, used to measure the ability of the agent to 
produce disease under controlled conditions, and often quantifi ed by a statis-
tic known as lethal dose 50, or LD 50 .This means the individual dose or numbers 
of the agent required to kill half (50%) of a specifi ed susceptible population in 
controlled conditions. 
Pathogenicity is an epidemiological term used to describe the ability of an 
agent of known virulence to produce disease in a range of hosts under a range 
of environmental conditions.
From Swinton (2002):
Latent period: The time from infection to when the individual is infectious to 
others. Also referred to as the “preshedding period”.
Incubation period: The time that elapses between infection and the appear-
ance of symptoms of a disease.
8Abstract
The monitoring and control of infectious animal diseases, limiting or prevention 
of their spread and efforts towards their eventual eradication are central tasks of 
the veterinary civil service. In addition to the cost-effectiveness of prophylaxis over 
disease and treatment, the animal welfare aspect is also involved. The purpose of 
this work is to review, describe and assess the available control measures against 
selected viral infections or diseases of domestic ruminants. 
The selected infections or diseases are bovine viral diarrhoea / mucosal disease 
(BVD), infectious bovine rhinotracheitis / infectious pustular vulvovaginitis (IBR), en-
zootic bovine leukosis (EBL) and maedi–visna (MV) of sheep. Each is recognized as 
a signifi cant disease of domestic animals. Decisive control and eradication meas-
ures are necessarily based on the biological, veterinary and diagnostic character-
istics of the affl ictions, as well as on their epidemiology in terms of the intrinsic 
determinants of the hosts, host–agent relationships and sources and transmission 
of the infection, and occurrence of these infections or diseases. This information 
is compiled and presented in the fi rst part of the thesis with special reference to 
available or possible control and eradication measures. These measures and pro-
grammes against the four affl ictions employed in major cattle and sheep produc-
ing countries in individuals and herds and on national and international levels are 
outlined and assessed briefl y.
In the descriptive part of the thesis the domestic and EU legislation that forms the 
offi cial framework for disease control and eradication are outlined. The develop-
ment in the situation concerning these four infections or diseases is described from 
the early records to date. The fi rst recorded entries of the occurrence of BVD and 
EBL in Finland date back to the 1960s, those of IBR to the beginning of the 1970s 
and of MV to the beginning of the 1980s. Large-scale surveillance and health moni-
toring among dairy, suckler-cow and beef herds and sheep fl ocks, starting during 
the fi rst half of the 1990s, enabled the estimation of actual prevalences of these 
infections and diseases. A common feature of the occurrence of these infections or 
diseases is that none has had a prevalence of more than an estimated few percent 
before 1990, and a maximum of 1% since then. This has formed a very favourable 
starting point for the nation-wide control and eradication measures. The volun-
tary control programmes or schemes, as well as the offi cial control and eradica-
tion measures are described. The successful eradication of IBR and EBL in 1994 and 
1996, respectively, and the signifi cant reduction in the occurrences of BVD and MV 
from 1990 to date, are reported in detail. 
The effi cacies of the offi cial control and eradication measures and of the actions of 
the voluntary control programmes or schemes are analyzed further, making use of 
a heuristic formulation for the infection reproduction number (R), i.e. the number 
of secondary cases produced by one infective animal. The infl uence of the meas-
ures is resolved into the three components of R: the probability of transmission, 
frequency of infectious contacts and length of the infectious period, and the im-
pact of the measures on each component is graded on a three-step scale. 
9The conclusion is drawn that the offi cial measures complemented by voluntary ac-
tions for control and eradication have for the most part been adequate. The sig-
nifi cance of fi nancial compensation from the state for the costs incurred in the 
control of notifi able diseases is noted. In the case of BVD the decisive measures for 
fi nal eradication have only been available since 2004 and their impact will be seen 
in the next few years. The role of continued surveillance and health moni toring for 
both overseeing the situation with BVD and MV, and maintaining an IBR and EBL-
free status is emphasized.
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1 Introduction
Determined disease control in Finland has led to the situation where there are, at 
least for the present, few important infectious diseases in domestic production an-
imals. Many of the OIE A- and B-list diseases of ruminants have either never been 
detected in Finland or not for a long time. None of the bovine diseases present, 
namely paratuberculosis, babesiosis, cysticercosis and malignant catarrhal fever, 
has a signifi cant prevalence (MMM, 2004). Of the bovine diseases or infections in 
the OIE other diseases list, salmonellosis, bovine viral diarrhoea, cryptosporidiosis 
and toxoplasmosis, and infections caused by Campylobacter jejuni / coli, verocyto-
toxigenic Escherichia coli and Listeria monocytogenes have been recorded, but the 
prevalence of each is either low or insignifi cant. However, respiratory infections, 
especially in young animals, caused by bovine respiratory syncytial, corona and 
parainfl uenza viruses are prevalent. The only OIE B-list diseases of sheep and goats 
possibly present are maedi–visna and scrapie, and of the other diseases listed only 
infections by L. monocytogenes. All three are encountered only occasionally, if at 
all (MMM, 2004).
The moni toring and control of infectious animal diseases, limiting or prevention 
of their spread and efforts towards their eventual eradication are central tasks of 
the veterinary civil service. The cost-effectiveness of disease prevention compared 
to that of disease and treatment is appreciated on both herd and national econ-
omy levels. This is refl ected by existing animal health and national food quality 
programmes, and the comprehensive national and EU legislation concerning infec-
tious animal diseases. The logic of animal disease control has been tabulated by 
Willeberg (2005, modifi ed):
Prevalence Goals Strategies 
Endemic Determine and Control agent
 reduce occurrence Identify and control
 Prevent spread risk factors
 Reduce impact Improve resistance
  Surveillance
Sporadic or Determine occurrence Surveillance
epidemic Prevent spread Strategic vaccination
 Eradicate Quarantine, movement
  control, zoning
Free Assess and reduce Contingency plans
 risk of (re)introduction Risk mitigation
 Preparedness Documenting freedom
  Surveillance
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This dissertation will not further explore the economic aspects of disease control 
and eradication. While acknowledging the realities of the agricultural industry the 
stand is taken that the prevention of unnecessary pain and suffering of animals has 
an intrinsic value beyond mere counting of costs. The EU directive 98 / 58 / EC laid 
down general rules for the “protection of animals of all species kept for the pro-
duction of food, wool, skin or fur or for other farming purposes”. These rules are 
refl ected in the “Five Freedoms”, as adopted by the Farm Animal Welfare Council 
and quoted in the EU Animal Health and Welfare Internet site (EU, 2005). The third 
of the fi ve is “Freedom from pain, injury and disease – prevention or rapid treat-
ment”. Furthermore, the reformed common agricultural policy (CAP), which will 
be introduced in the EU during 2005−2009, will contain as a key element a ´single 
farm payment` system. This system is closely linked to compliance with rules on ani-
mal welfare, among others.
The best way to prevent the occurrence of a disease is to eradicate it and to en-
sure subsequent freedom of the disease with suffi cient control measures. In many 
cases this is an option only with outbreaks of economically devastating diseases or 
human life threatening zoonoses, such as foot-and-mouth disease or rabies. The 
eradication of endemic and prevalent diseases that produce only mild or inappar-
ent symptoms may be considered impractical if not impossible, especially if the 
suggested control measures are deemed unreasonably exacting or otherwise ex-
treme. 
The objectives of this thesis are fi rst to examine the biological, veterinary and es-
pecially the epidemiological characteristics described in the literature of four viral 
infections or diseases of domestic ruminants: bovine viral diarrhoea / mucosal dis-
ease (BVD / MD), infectious bovine rhinotracheitis / infectious pustular vulvovaginitis 
(IBR / IPV), enzootic bovine leukosis (EBL), and maedi–visna (MV) of sheep. This back-
ground information is compiled with special reference to the possible or available 
control measures both on individual, herd, and country-wide levels. The available 
information of the actual control measures applied especially in member states of 
the European Union and the Scandinavian countries is also reviewed and the meas-
ures assessed briefl y. 
Secondly, the objective is to review the legal framework for the disease control 
activities, and to describe in detail the control, eradication and surveillance meas-
ures applied in Finland. BVD / MD falls in Finland into the “Endemic”, MV into the 
“Sporadic” while IBR / IPV and EBL fall into the “Free” category of Willeberg (2005, 
above). The development in the situation of the four infections or diseases from 
the sixties to date, as a result of applying these measures, is described thoroughly. 
Thirdly, the effi cacies of the control and eradication measures applied in Finland 
are assessed employing a heuristic formulation of a central theoretical concept 
of infectious disease epidemiology, the infection reproduction ratio (R), i.e. the 
number of secondary cases produced by an infective animal. The three compo-
nents of the formulation are the probability of transmission, the frequency of in-
fectious contacts and the length of the infectious period, and the impact of the 
measures on each component is graded on a three-step scale.
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2 Review of the literature
2.1 Description of the diseases
2.1.1 Bovine viral diarrhoea / Mucosal disease (BVD / MD)
Aetiology
Bovine viral diarrhoea / mucosal disease, BVD / MD or BVD for short, is caused by a 
pestivirus in the Flaviviridae family. The genome of the virus (BVDV) is a single-
stranded, positive sense ribonucleic acid molecule of approximately 12 500 nucleo-
tides. The virion core is icosahedral and the spherical enveloped virus particle is 
40–60 nm in diameter (Donis, 1995; ICTV, 2003). BVDV occurs in noncytopatho-
genic (ncp) and cytopathogenic (cp) forms (Corapi et al., 1988). These terms do not 
refer to the virulence of the virus in the fi eld but to the effect of the strains on 
cell culture. However, these two types behave differently in the host animal. Ncp 
strains produce viremia and are excreted by the animal while cp types do not pro-
duce viremia or infect the foetus and are poorly excreted (Lambot et al., 1998). 
Two antigenically distinct genotypes, 1 and 2, have been recognized; both may oc-
cur in ncp and cp forms (Ridpath et al., 1994). However, the genotyping itself was 
based on the 5’ untranslated region, which does not code for structural proteins. 
Genome characterization studies have shown extensive antigenic and genetic di-
versity among BVDV type 1 strains, and subtypes or genetic clusters 1a through 
1d have been described (Vilcek et al., 2005; Baule et al., 2001). Mucosal disease 
results from a process in persistently infected (PI) animals whereby the persisting 
ncp strain mutates to cp, or there is a recombination of the ncp strain with an ex-
ogenous superinfecting cp strain (Kummerer et al., 2000, Tautz et al., 1998). BVDV 
is closely related to classical swine fever and border disease of sheep viruses. How-
ever, it has been pointed out (Edwards and Paton, 1995) that the virological nomen-
clature of pestiviruses based on the host species is increasingly unsatisfactory.
Intrinsic determinants of the agent
Infectivity The order of magnitude of the infectious dose is some 2000 TCID 50 by 
the intranasal and 1–2 TCID 50 by the subcutaneous route (Cook et al., 1990). A dose 
similar to the subcutaneous dose was also suffi cient intramuscularly (Antonis et al., 
2004). Thus, it appears that the TCID 50 and the ID 50 do not differ if the animals are 
exposed parenterally. Judging from the slow or limited spread of the transient in-
fection within a herd, the contact infectivity is qualitatively at most of a medium 
level. 
Virulence An acute infection LD 50 has not been reported for BVDV. The infection 
in adults frequently runs a subclinical course, while young animals are more prone 
to develop actual symptoms. Genotype 2 is considered more virulent than geno-
type 1. For example, the thrombocytopenic strains responsible for the hemorrhagic 
syndrome observed in Northern America are of genotype 2 (Odeon et al., 1999, 
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Ellis et al., 1998). However, Goens (2002) pointed out that genotype 2 has been 
present for a long time and in other parts of the world where severe acute BVD is 
rare, or has not been reported. The mucosal disease displays a higher level of viru-
lence of BVDV: the condition is invariably lethal (Baker, 1995).
Pathogenicity BVDV is able to infect a wide range of both domestic and wild un-
gulate species (Lindberg, 2002; Løken, 1995).
Persistence If a foetus is infected by ncp-BVDV before it develops immunocom-
petence (during the fi rst trimester of gestation), tolerance can ensue and the virus 
can persist in the animal (PI animal) for life (Done, 1980). The persistence is associ-
ated with the failure of ncp-BVDV to induce type I interferon in comparison to cp 
strains, and not because the uterus is refractory to the cp form of the virus (Charles-
ton et al., 2001).
Pathogenesis and the clinical picture
The acute transient BVDV infection lasts 2–3 weeks. The infection causes leuko-
penia and thrombocytopenia, and impairs the cellular immunity functions (Corapi 
et al., 1989; Bruschke et al., 1997). BVD in young animals is characterized by fever, 
inappetence, respiratory symptoms and diarrhoea (Tråven et al., 1991). The infec-
tion in susceptible adult cows is in most cases subclinical or there is only a tempo-
rary dip in the milk production. Acute forms of the disease associated with high 
mortality, often with hemorrhagic syndrome, have also been described (Pellerin et 
al., 1994; Ridpath et al., 2005). BVDV can cross the placenta and infect foetuses of 
all ages (Lindberg, 2002). Infection during the fi rst 4 months of foetal development 
may, in addition to the development of a PI foetus, cause embryonic re sorption, 
abortion and intrauterine growth retardation. Congenital malformations of the 
eye and CNS can result from infections that occur between the fourth and sixth 
months of foetal development. Mummifi cation, premature birth, stillbirth, and the 
birth of weak calves are also possible outcomes of foetal infection (McGowan and 
Kirkland, 1995; Fray et al., 2000). The PI animals shed the virus continuously in all 
secretions and excretions (Brock et al., 1991); they can show impaired growth and 
lack of thriftiness but can also appear clinically normal. PI cows can conceive and 
give birth to calves that will also be PI animals (Baker, 1987). In adult bulls the in-
fection can have an effect on semen quality and the infection can be transmitted 
via the semen collected during the infection. The mucosal disease of PI animals ap-
pears between 6 months and 2 years of age. In the acute form it is characterized by 
fever, anorexia, extensive mucosal erosions throughout the alimentary canal, pro-
fuse diarrhoea and wasting, and death within 3 weeks (Baker, 1995). Chronic MD 
can also present dermatological lesions and laminitis and the animal may survive 
for several months (Lindberg, 2002).
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Diagnostic aspects
There are no pathognomonic clinical signs of infection with BVDV in cattle. With 
the distinct exception of classical MD, especially adult animals frequently show no 
signs at all or the signs are very unclear (Lindberg, 2002). Diagnostic investigations 
must therefore rely on laboratory-based detection of the virus or virus-induced im-
mune response in submitted samples. The methods are the same for both geno-
types 1 and 2.
Detection of virus or viral components
Three methods for detecting BVDV can be distinguished. The virus may be prop-
agated in cell culture (Brock, 1995; OIE, 2004) or BVDV antigens can be demon-
strated either immunohistochemically in organ samples using specifi c antibodies 
(Haines et al., 1992, Grooms and Keilen, 2002), or with ELISAs employing immo-
bilized capture antibody and a detector antibody conjugated to a signal system 
(Kramps et al., 1999). The major viral antigens detected this way are referred to 
as E rns (previously E0 or gp48) and NS2-3 (previously p80 / p125) (Sandvik, 2005). 
A third alternative is direct detection of viral RNA using molecular tools, such as 
reverse transcription–polymerase chain reaction (RT-PCR; Weinstock et al., 2001; 
Mahlum et al., 2002). RT-PCR should be targeted at the highly conserved 5’ un-
translated region of the genome to ensure that all relevant genetic subgroups are 
detected (Sandvik, 2005). Multiplex assays have also been developed where both 
genotypes of the virus can be determined simultaneously (Gilbert et al., 1999). 
However, genotyping the virus to diagnose BVD is of little relevance (Goens, 2002). 
Isolated strains or amplifi ed parts of the viral genome can further be sequenced 
and the sequence information used for epidemiological and eradication purposes 
(Ståhl et al., 2005). Confi rmation of the mucosal disease diagnosis requires dem-
onstration of the cp type of BVDV. Ideally, the presence of both cp and ncp types 
should be shown.
Detection of an immune response against BVDV
Cellular immunity, measured as the proliferation of peripheral blood monocytes 
(“lymphocyte proliferation assay”), has been described (Larsson and Fossum, 1992). 
However, most studies of the immune response to BVDV have focused on humoral 
immunity. The major antigens against which the antibodies are produced are re-
ferred to as E1 and E2 (Sandvik, 1999). The antibodies produced by an immuno-
competent animal can be detected from 2–3 weeks to years after an acute infec-
tion. A broad variety of serological tests has been adopted for BVDV serology. 
The reference assay has for a long time been the virus neutralization (VN) test 
(Edwards, 1990), which primarily detects antibodies against E2 (Sandvik, 2005). 
While sensitive and specifi c, it requires careful standardization and moni toring of 
the cell culture and media used, and is not optimal for examining a few occa-
sional samples. Enzyme immunoassays, such as ELISAs, offer a rapid, robust and a 
high-throughput method not only for serum but also for bulk-tank milk samples 
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from non-vaccinated dairy herds (Niskanen et al., 1989, Niskanen, 1993), making 
it suit able for large-scale screening. The most common ELISAs apply the indirect 
approach, where the immobilized antigen is used to trap the specifi c antibodies, 
which are then detected using species-specifi c anti-antibodies conjugated to some 
signal system. Other serological tests used include immunodiffusion in agar gel, 
complement fi xation, indirect immunofl uorescence and Western blotting (Sand-
vik, 1999). Seronegativity combined with isolation of cp BVDV is the best confi rm-
ation of MD, while seronegativity combined with isolation of ncp BVDV is the best 
confi rmation of a persistent BVDV infection (Goens, 2002).
Performance of diagnostic tests suitable for screening
In testing 1000 fi eld serum samples, the BVDV antigen ELISA of Kramps et al. (1999) 
showed 99% specifi city and 98% sensitivity relative to the VN test. The manu-
facturer of a commercial kit for detecting BVDV quotes fi gures of 100% for both 
se and sp (HerdChek, IDEXX Corp. USA). The single-tube single-enzyme RT-PCR as-
say (Weinstock et al., 2001) was shown to be a sensitive and specifi c test for the 
detection of BVDV in bovine serum pooled in lots of up to 100 samples. The manu-
facturer of a commercial kit for detecting antibodies against BVDV quotes fi gures 
of 100% se and 98.2% sp for serum samples relative to the VN test, and 95.2% se 
and 100% sp for milk samples relative to serum (SVANOVA BVDV-Ab, Svanova Bio-
tech AB Sweden). 
2.1.2 Infectious bovine rhinotracheitis / Infectious pustular 
vulvovaginitis (IBR / IPV)
Aetiology
IBR / IPV, or IBR for short, is caused by bovine herpesvirus 1 (BHV-1) in the genus 
Varicellovirus of the subfamily Alphaherpesvirinae, which belongs to the Herpes-
viridae family. The genome of the virus is linear double-stranded DNA of approxi-
mately 125 300 base pairs. The virion core is an icosapentahedral nucleocapsid, 
100 nm in diameter and composed of 162 capsomers; the pleomorphic enveloped 
virus particle is about 150–200 nm in diameter (ICTV, 2004a). Only a single serotype 
of BHV-1 is recognized, but subtypes of it are distinguished on the basis of restric-
tion enzyme cleavage patterns of the viral DNA (Metzler et al., 1985). These types 
are referred to as 1.1 (respiratory subtype) and 1.2 (respiratory and genital sub-
type). The subtype 1.2 has been further classifi ed with molecular tools into 2a and 
2b. The former encephalitic subtype 1.3 has been reclassifi ed as a distinct herpes-
virus, designated as BHV-5 (Roizman et al., 1992).
Intrinsic determinants of the agent
Infectivity Intranasally, a dose of 10 7.7 TCID 50 was suffi cient to infect cattle in age 
groups 2 and 5 weeks, and 6 and 18 months (Msolla et al., 1983). Straub (1987) 
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determined that the intranasal infective dose was 3.2 TCID 50 for a virulent strain, 
while 32 TCID 50 / dose of AI semen were not suffi cient to infect any of 44 insemi-
nated dams (Goffaux et al., 1976). However, Turin et al. (1999) estimated that the 
minimal dose to infect a cow by AI was 32 infectious viral particles. 
Virulence The LD 50 of BHV-1 infection has not been reported. Morbidity to the 
infection approaches 100% and mortality may reach 10%, particularly if complica-
tions occur. The subtype 1 is generally considered more virulent than subtype 2 (Ed-
wards et al., 1991), but the virulence of BHV-1.1 and BHV-1.2 in genital infections 
of bulls has not been compared (Vogel et al., 2004).
Pathogenicity While BHV-1 causes infections predominantly in domestic and wild 
cattle (OIE, 2004), it has occasionally been isolated from cases of vaginitis and bal-
anitis in swine and from aborted equine fetuses (Murphy et al., 1999).
Persistence The virus proceeds from the primary mucosal lesion by neuronal 
axonal transport in a naked nucleocapsid form to the nearest ganglion, usually 
trigeminal or sacral (dorsal root), and the viral DNA either causes a cytolytic in-
fection or establishes a persisting latent infection (Jones, 1998). A wide variety of 
stimuli, such as stress, transport, parturition and treatment with glucocorticoids 
may reactivate the infection and lead to secretion of the virus. The mechanisms of 
latency and reactivation have been extensively studied, but the details are not yet 
fully understood (Inman et al., 2002). It has been shown that only a small region of 
the viral genome, referred to as “latency-related” (LR), is transcriptionally active in 
latently infected neurons (Turin et al., 1999). The LR gene products may even pro-
mote neuronal survival by inhibiting programmed cell death (Ciacci-Zanella et al., 
1999), thereby also sustaining the infection in the cell.
Pathogenesis and the clinical picture
An uncomplicated acute respiratory or genital infection lasts for 5–10 days. BHV-1 
causes leukopenia and a lack or diminished number of macrophage-granulocytes, 
MHC class II antigen presenting cells, as well as reduced cytokine secretion in the 
lung and regional lymphoid tissue (Tikoo et al., 1995). Other effects of the infec-
tion that induce immunosuppression include down-regulation of the expression 
of MHC class I molecules on the surface of infected cells and interference with the 
protective function of CD8 + cytotoxic T lymphocytes (Turin et al., 1999). The ani-
mals mount a vigorous humoral response that lasts for over 5 years (Chow, 1972). 
However, the immune response is not able to eliminate the persistent infection. 
Maternal antibodies can interfere with the development of an active antibody re-
sponse to antigen, but do not necessarily prevent virus replication and the estab-
lishment of a latent infection (Lemaire et al., 1995). This can result in seronegative 
latent carriers of the virus, which has been demonstrated experimentally (Lemaire 
et al., 2000). The infection in adults is frequently mild or runs a subclinical course. 
The clinical signs of the respiratory form (IBR) include a serous progressing to a mu-
copurulent nasal discharge, conjunctivitis which may be accompanied by corneal 
opacity, salivation, infl amed nares (“red nose”), fever, and a lack of appetite (Wyler 
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et al., 1989). In uncomplicated IBR infections, most lesions are restricted to the up-
per respiratory tract and trachea. BHV-1 infection is an important component of 
the upper respiratory tract infection referred to as “shipping fever” or bovine res-
piratory complex (Tikoo et al., 1995). The genital form (IPV), pustular vulvovaginitis 
in cows and pustular balanoposthitis in bulls, is characterised by a mild to purulent 
vaginal discharge and necrotic lesions in vaginal or preputial mucosae. Other mani-
festations of BHV-1 infection include abortion, endometritis and a systemic disease 
affecting the visceral organs in young calves (Wyler et al., 1989).
Diagnostic aspects
Subclinical infection or mild respiratory signs do not readily suggest an infection 
by BHV-1, as it must be differentiated from several other viral respiratory proc-
esses, such as infection with respiratory syncytial or coronavirus. However, fulmin-
ant IBR or IPV does produce more distinguishable symptoms that, in connection 
with patho logical and epidemiological signs, can arouse distinct suspicion. Labora-
tory examination is required to make a defi nite diagnosis.
Detection of virus or viral components
Four methods for detecting BHV-1 can be distinguished. The virus may be propa-
gated in cell culture using, for example, primary or secondary bovine kidney, lung 
or testis cells, or established cell lines such as the Madin-Darby kidney cell line 
(OIE, 2004), and demonstrated in the culture with neutralizing monoclonal anti-
body, by immunofl uorescence or the immunoperoxidase test. BHV-1 antigens can 
be demon strated either in swab smears with direct or indirect fl uorescent anti-
body tests or immunohistochemically, or in tissue samples by immunofl uorescence 
(Edwards et al., 1983). The viral antigen can also be detected with ELISAs employ-
ing im mobilized capture antibody and a detector antibody conjugated to a signal 
system (Collins et al., 1988). The fourth alternative is direct detection of viral DNA 
using molecular tools, such as DNA–DNA hybridization or the polymerase chain 
reaction (PCR). The latter has been used in the detection of viral DNA in infected 
semen samples (van Engelenburg et al., 1993), but it is not yet an internationally 
recognized diagnostic tool (OIE, 2004).
Detection of an immune response against BHV-1
Tests for cell-mediated immunity include tests for delayed type hyper sensitivity, 
leuko cyte migration factor and granulocyte migration inhibition factor in the pres-
ence of BHV-1 antigen (Deptula, 1994). Interleukin-2 production has also been 
used to measure the cell-mediated immune response to BHV-1 (Miller-Edge and 
Splitter, 1986).
Tests for humoral immunity: A variety of tests have been used to detect antibodies 
against BHV-1 both in serum and in milk. Virus neutralization tests are performed 
19
with many modifi cations; these refer to the virus strain, the cell culture or line 
used, and to actual procedural variations. The test is sensitive and specifi c but re-
quires careful standardization. ELISAs offer a feasible alternative to VN and many 
versions have been described (Kramps et al., 1993). Indirect ELISA is the most com-
mon, but as yet there are no standard procedures for ELISAs (OIE, 2004). ELISAs 
can also be used to detect antibodies in bulk-tank milk. A third alternative to test-
ing samples for antibodies against BHV-1 is the indirect fl uorescent antibody test 
(Welle mans and Leunen, 1973, referred to in OIE, 2004).
Performance of diagnostic tests suitable for screening
In a comparative ring test among European laboratories using a set of reference 
sera and sera and milk samples from experimentally-infected and vaccinated ani-
mals, the sensitivity and specifi city of VN for sera was 93% and 96%, that of indi-
rect ELISA 87% and 99%, and of glycoprotein E (gE) specifi c ELISA 72% and 92%, 
all respectively (Kramps et al., 2004). The gE ELISA is the only test able to distin-
guish between infected and vaccinated animals. The indirect ELISA showed a sensi-
tivity of 98% and a specifi city of 93% for milk samples while the corresponding fi g-
ures for gE ELISA were 58% and 88% (Kramps et al., 2004). The manufacturer of a 
commercial kit for detecting antibodies against BHV-1 (SVANOVA IBR-Ab, Svanova 
Biotech AB Sweden) quotes fi gures 100% se and 92% sp for serum samples relative 
to VN, and 92.8% se and 100% sp for milk samples relative to serum. 
2.1.3 Enzootic bovine leukosis (EBL)
Aetiology
The epidemiological cause of EBL is bovine leukosis virus (BLV), an oncogenic delta-
retro virus in the Retroviridae family. The genome of the virus consists of two iden-
tical single-stranded RNA subunits of 8 714 nucleotides associated with several 
structural proteins, such as nucleo- and nucleocapsid proteins, and enzymes in-
cluding reverse transcriptase. The actual length of the RNA molecule may slightly 
vary depending on the strain. The virion core is icosahedral and the enveloped vi-
rus particle is 100–120 nm in diameter (ICTV, 2004b). The genus Deltaretrovirus also 
includes primate and human T-lymphotropic viruses (ICTV, 2002).
Intrinsic determinants of the agent
Infectivity Studies on BLV infectivity have used the number of infected cells rather 
than of virus particles as the dose. Thus, 2000–20 000 BLV-infected lymphocytes, 
given intravenously, transmitted the agent to susceptible calves (Klintevall et al., 
1997). In a separate study, 12% of steers receiving 10 000 lymphocytes and 62% of 
steers receiving 50 000 lymphocytes subcutaneously acquired BLV infection (Buxton 
and Schultz, 1984). Gatei et al. (1989) determined that a low dose of 200 infected 
bovine B-lymphocytes given intravenously in diluted whole blood was enough to 
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start the infection in sheep. A dose of 3.9 × 10 9 and 3.9 × 10 8 lymphocytes given 
as a rectal inoculation of infected bovine blood to cows and sheep, respectively, 
started the infection in all animals (Henry et al., 1987). On the other hand, leuco-
cyte-free semen from BLV-infected bulls, given intraperitoneally, did not infect any 
of the challenged sheep (Kaja and Olson, 1982). 
Virulence Actual LD 50 estimates for the slow infection have not been reported. 
A large proportion of the infected animals remain asymptomatic. Some 30–70% 
of infected cattle develop persistent lymphocytosis (PL), and only 0.1–10% develop 
lymphosarcomas (LSA). The latter condition is usually fatal (OIE, 2004). 
Pathogenicity BLV is the agent of chronic lymphatic leukaemia / lymphoma in 
cows, sheep and goats. Infection without neoplastic transformation has also been 
observed in capybaras and water buffalos, and can experimentally be obtained in 
pigs, rabbits, rats, cats, dogs, deer and some primates (Burny et al., 1980).
Persistence After entry into the host cell (predominantly B-lymphocyte) the 
virion-associated reverse transcriptase generates a double-stranded DNA copy of 
the viral RNA, and the proviral DNA is then integrated into the host chromosome. 
The process involves the long terminal repeat (LTR) sequences that fl ank the vi-
ral genome (Fine and Sodrosky, 2000). The proviral DNA can also exist in both un-
integrated linear and circular forms in the cell (Reyes and Cockerell, 1996). The la-
tency ensues from blocking the expression of the provirus on the transcriptional 
level, but the actual molecular mechanisms are still incompletely understood. Once 
integrated, the proviral DNA stays in the chromosome for the life of the cell. The 
silencing of the provirus is also important in the long-term persistence of infection 
(Tajima et al., 2003).
Pathogenesis and the clinical picture
Cattle may be infected at any age, including the embryonic state. The incubation 
time to clinical signs (LSA) is typically > 3 years. In addition to PL, a polyclonal ex-
pansion of IgM+, CD5+ B cells, the BLV infection may also lead to persistent B-
cell lymphopenia (Beyer et al., 2002). Progression to PL in BLV-infected cattle was 
shown to correlate with CD4+ T cell dysfunction in response to BLV antigens (Or-
lik and Splitter, 1996) and to require a genetic predisposition (Ferrer, 1979). It has 
been demonstrated that bovine major histocompatibility (bovine lymphocyte anti-
gen, or BoLA) types correlate with the risk of infection as well as the development 
of PL and LSA (Stear et al., 1988), and that BoLA alleles conferring resistance or 
susceptibility may vary according to breed (Bernoco and Lewin, 1989; Hopkins and 
DiGiacomo, 1997).
PL is considered as a benign lymphoproliferative condition, characterized by 
lympho cyte counts above 7 500 cells / mm 3 (Timoney et al., 1988). The presence of 
integrated provirus in a few specifi c sites is one of the factors that can promote dif-
ferentiation from the non-neoplastic to the neoplastic condition (Kettmann et al., 
1980). The virus is a C-type oncovirus and does not encode viral oncogenes (v-onc −) 
(Timoney et al., 1988). It carries a transactivating gene, tax, which is required for 
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replication and can transactivate several cellular genes whose expression could 
lead to transformation (Twizere et al., 2000). Furthermore, one of the gene prod-
ucts (G4) encoded by the so-called region X at the 3’ end of the genome has shown 
oncogenic potential (Kerkhofs et al., 1998). The details of the monoclonal neo-
plastic transformation of B cells are still incompletely known. In LSA, lymph nodes 
and a wide range of tissues are infi ltrated by neoplastic cells. Organs frequently in-
volved are the abomasum, right auricle of the heart, spleen, intestine, liver, kidney, 
omasum, lung, spinal cord and uterus (OIE, 2004). Cattle with PL frequently show 
no clinical signs, whereas the signs associated with LSA will depend on the site of 
the tumors, and may include digestive disturbances, emaciation, general debility, 
and sometimes neurological manifestations. Cattle with LSA almost invariably die, 
either suddenly or within months after the onset of clinical signs (OIE, 2004).
Diagnostic aspects
Animals with PL can usually be detected only from samples tested in the labora-
tory either haematologically (Bendixen, 1965) or serologically. LSA-associated di-
gestive disturbances, weight loss, lameness, or even dark blood in the faeces due 
to tumorous abomasal ulcers are not pathognomonic. However, animals with LSA 
frequently have enlarged and fi rm superfi cial lymph nodes and uterine and pel-
vic node tumors that may be detected by rectal palpation. These signs, as well as 
tumor masses in intestinal organs encountered in meat inspection, may arouse 
more distinct suspicion. However, defi nite diagnosis of LSA requires histopatho-
logical examination of the neoplastic tissue, and serological testing for antibodies 
against BLV. 
Detection of the virus and viral components
There are basically two methods to demonstrate the presence of the agent. The 
virus may be isolated by separating the mononuclear cells from blood, incubating 
them either with or without foetal bovine lung cells, and testing for capsid p24 
and envelope gp51 antigens in the culture supernatant (OIE, 2004). The BLV may 
also be detected as the provirus using PCR or nested PCR, followed by gel electro-
phoresis and staining (Rola and Kuzmak, 2002). The latter is considered to be the 
most rapid and sensitive method (Beier et al., 1998; OIE, 2004).
Detection of immune response against BLV
Tests for cell-mediated immunity are not in routine use in BLV infection diagnos-
tics. Changes in immune functions with several tests measuring neutrophil func-
tions and mononuclear cell subset analysis in animals experimentally infected with 
BLV have been studied by Flaming et al. (1997), among others. 
Tests for humoral immunity: The antibodies most readily detected are those di-
rected towards the envelope glycoprotein gp51 and capsid protein p24. The two 
most common serologic tests are or have been AGID and indirect or blocking 
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ELISAs; both are prescribed tests for international trade (OIE, 2004). The indirect 
ELISAs can be used for both serum and milk samples. International (OIE) standard 
sera are available for calibration of the ELISA assays. 
Performance of diagnostic tests suitable for screening 
Choi et al. (2002) assessed the diagnostic sensitivity and specifi city of commer-
cial agarose immunodiffusion (AGID) and the antibody capture enzyme immuno-
sorbent assay (EIA) for the detection of antibodies against BLV, using Western blot-
ting as the standard. The two tests failed to detect 39% and 35%, respectively, of 
the animals determined positive by the Western blot test. There are also other re-
ports (e.g. Trono et al., 2001; Dolz and Moreno, 1999) suggesting that screening 
with AGID or some EIAs is not suffi cient to identify all positive animals. Reichel et 
al. (1998) tested fi ve ELISA kits with a set of well-defi ned sera (including reference 
sera from OIE) and compared the results with those obtained with AGID and the 
electrophoretic immunoblotting (EIB) test. The performance of the ELISAs ranged 
from 88 to 99% correct classifi cation. The ELISA tests detected about 10% more re-
actors than the combined AGID and EIB tests. A commercial test (CHEKIT-Leucotest, 
Dr. Bommeli AG, Switzerland) for antibodies in bulk-tank milk showed 97% sensi-
tivity but only 44% specifi city in relation to AGID, after the sensitivity and specifi -
city of the latter was accounted for (Sargeant et al., 1997b). The manufacturer of 
another commercial kit for detecting antibodies against BLV gp51 (SVANOVA BLV-
gp51-Ab, Svanova Biotech AB Sweden) quotes fi gures of 100% se and 93.4% sp for 
serum samples relative to AGID. The test is claimed to detect the standardized inter-
national reference serum E4 at a dilution of 1 / 40 000 in milk.
2.1.4 Maedi–visna (MV) of sheep 
Aetiology
Maedi (respiratory), visna (nervous system, wasting), and arthritic forms of the dis-
ease are caused by a retrovirus in the Lentivirinae subfamily of the Retroviridae. 
The genome of the virus (MVV) consists of two copies of viral RNA associated with 
one (p7) of the structural gag gene proteins. The length of the RNA molecule 
depends somewhat on the strain; the EMBL databank strains vary between 9189 
and 9225 nucleotides (EMBL, 2005). The virion core is a cylindrical nucleocapsid, 
and the enveloped virus particle is approximately 100 nm in diameter (Clements 
and Zink, 1996; ICTV, 2004c). MVV is genetically closely related to caprine arth ritis-
encephalitis virus (CAEV), and together these two are often referred to as small 
ruminant lentiviruses (SRLV) (Blacklaws et al., 2004), or occasionally as ovine lenti-
viruses (OvLV) (Clements and Zink, 1996). It has even been suggested (Valas et al., 
1997) that North American and French caprine arthritis-encephalitis viruses have 
emerged from ovine maedi–visna viruses and that sheep to goat transmission of 
SRLV is frequent (Shah et al., 2004).
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Intrinsic determinants of the agent
Infectivity The ID 50 of colostrum or milk has not been reported, but the minimal 
infectious dose has been determined as 10 TCID 50 via the trachea and 10 7 TCID 50 
via the intranasal route (Torsteinsdottir et al., 2003). Lairmore et al. (1986) infected 
fi ve newborn lambs intratracheally with 10 4 – 3.1 × 10 6 TCID 50 of OvLV; each devel-
oped interstitial pneumonia by 4 weeks of age.
Virulence The LD 50 for the slow infection has not been reported. The virus may be 
carried for the life of the animal without any clinical signs, but if they appear the 
condition is eventually fatal. The mortality may reach 20–30% in newly-infected 
animals (Sigurdsson et al., 1952). There is some indication of breed pre disposition 
to the clinical illness (Timoney et al., 1988; Straub, 2004).
Pathogenicity The host range of MVV is sheep and goats, although there is some 
serological evidence of SRLV infection in wild ruminants, mouffl on, ibex and cham-
ois, which are related to sheep and goats (Morin et al., 2002).
Persistence After entry into the host cell the virion-associated reverse tran-
scriptase generates a double-stranded DNA copy of the viral RNA. The virion asso-
ciated integrase then integrates the proviral DNA into the host chromosome; the 
long terminal repeat sequences that fl ank the viral DNA genome have a function 
in the process (Clements and Zink, 1996; Fine and Sodrosky, 2000). Once integrated 
the viral DNA stays in the chromosome for the life of the cell. The long term per-
sistence of the virus, in addition to the latency inside the cells, involves antigenic 
variation, probably due to mutations especially in the highly variable region of the 
env gene (Andrésdóttir et al., 2002). 
Pathogenesis and the clinical picture
The major host cells of MVV are cells of the monocyte-macrophage lineage (Gen-
delman et al., 1986). The incubation time can be several months to years until 
clinical signs appear (Houwers et al., 1987; OIE, 2004). Considerable virus replica-
tion takes place in the fi rst few weeks after infection, and during this acute phase 
the virus spreads throughout the host. Primary sites of viral replication include 
the lymph nodes, spleen and bone marrow (Clements and Zink, 1996). Infected 
monocytes mature into macrophages in the organs (lung, brain, joints), and the 
differentiation of the cells also activates viral gene expression (Gendelman et al., 
1986). However, the lack of a permissive system for virus replication in tissue cells 
and the fact that terminally differentiated (short-lived) macrophages are the only 
infected cells in tissue suggest a constant viral source. Gendelman et al. (1985) 
identifi ed clusters of infected macrophage precursors in bone marrow as such a 
source. Viral gene expression in tissue macrophages results in the development 
of an intense infl ammatory response. The nature of the infl ammatory reaction in 
each site is similar, consisting of an interstitial, mononuclear cell reaction, some-
times with large aggregates of lymphoid cells and follicle formation (OIE, 2004). 
The interstitial pneumonia in lungs is characterised by thickened, often fi brotic 
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interalveolar septa and peribronchial infi ltrates of lymphocytes and macrophages 
(Georgsson and Palsson, 1971). A large proportion of the infected animals develop 
an indurative mastitis and infected macrophages enter the milk from the infl amed 
mammary gland. In the brain there are intense perivascular infl ammatory cuffs, 
diffuse infi ltrates of lymphocytes and macrophages, frequently accompanied by 
demyelination (Petursson et al., 1976). Affected joints have hyperplastic synovial 
membranes with accumulation of plasma cells and macrophages in the subsynovial 
soft tissue. Advanced cases may show carpal bursitis, mineralization of the soft tis-
sues and erosion of the joint cartilage (Clements and Zink, 1996). Kidneys may also 
show vasculitis. 
The gross pathological fi ndings in maedi are usually restricted to the lungs, which 
are consolidated and do not collapse when the thoracic cavity is opened, and 
to the associated lymph nodes. The lungs and lymph nodes increase in weight 
(up to 2–3 times the normal weight) (OIE, 2004). Apart from neurogenic muscu-
lar atrophy, visna does not produce gross pathological signs. Major clinical signs 
of maedi include a dry cough, expiratory dyspnea, emaciation in spite of good 
feed intake, and strain-dependent mastitis and / or arthritis. The clinical course may 
last 3–8 months but the condition is eventually fatal. The major clinical signs of 
visna include weakness of the hind legs, progressing to complete paralysis. Some-
times other central nervous system disorders (ataxia, muscle tremors) are present. 
The clinical course may last several years, with periods of remission (Straub, 2004, 
Murphy et al., 1999). Arthritic processes are frequently seen in association with 
both maedi and visna, but a polyarthritis of especially the carpal and tarsal joints 
may also be the main presentation of the disorder (Cutlip et al., 1985). Variable 
degrees of all three forms may be seen naturally in the same animals (Timoney et 
al., 1988).
Diagnostic aspects
The onset of clinical signs is insidious and in both maedi and visna is seldom de-
tected in sheep less than 3 years of age. Weight loss and dyspnea in the early stages 
of maedi are not pathognomonic. The shepherds in Iceland are reported to have 
differentiated between “wota”, i.e. watery maedi and “purra”, i.e. dry maedi by 
lifting sick sheep by their hind legs. In cases of adenomatosis a copious amount 
of watery nasal discharge fl ows out of the nostrils, while in cases of dry maedi no 
nasal discharge is seen (Straub, 2004). Visna is also hard to detect before signs of 
paralysis of the hind legs set in. The arthritic processes can also have a diffuse ae-
tiology. Defi nite diagnosis, especially in the early stages of the diseases, requires 
confi rmation in the laboratory. 
Detection of the virus or viral components
The virus may be isolated from leucocytes of live animals by culturing the cells to-
gether with indicator cells, such as sheep choroid plexus cells, and observing the 
development of the cytopathic effect (CPE; OIE, 2004). The presence of viral anti-
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gen in CPE areas can be demonstrated, for instance, by immunolabelling. The vi-
rus may also be isolated from necropsy tissues (lung, synovial membranes, etc.) by 
making explant cultures and demonstrating the virus in the CPE areas, as above. 
The virus particles may also be detected in the CPE areas by electron microscopy, 
or indirectly by the reverse transcriptase assay. Adherent macrophage cultures can 
be established from lung-rinse material and virus production tested as described 
above (OIE, 2004). The virus may furthermore be demonstrated with nucleic acid 
recognition methods such as PCR, either directly from the proviral state or, com-
bined with reverse transcriptase polymerisation, from viral RNA. The amplifi cation 
is then followed by Southern blotting and in situ hybridization (Leroux et al., 1997; 
Extramiana et al., 2002). The latter techniques are especially useful in determining 
the infection status of animals that cannot be defi nitely diagnosed by serology, 
e.g. due to late seroconversion (Knowles, 1997).
Detection of an immune response against MVV
Even though cell-mediated immunity is invoked by the infection, tests for this type 
of immune response are generally not used in MVV infection diagnostics (OIE, 
2004).
Test for humoral immunity: The establishment of a positive antibody status is suf-
fi cient for the identifi cation of virus carriers (OIE, 2004). The two viral antigens of 
major importance in routine serology are envelope glycoprotein gp135 and core 
protein p28, although other proteins such as envelope protein p90 (Fevereiro et 
al., 1999) can also be used in the assays. The assays now commonly used are agar 
gel immunodiffusion (AGID) and whole-virus antigen ELISA (Houwers and Schaake, 
1987). Both are prescribed tests for international trade (OIE, 2004). Other tests 
used mainly in specialized laboratories are Western immunoblotting and immuno-
precipi tation. The milk antibody assay may also be appropriate if ewes are being 
milked.
Performance of diagnostic tests suitable for screening
The PCR-based methods to detect viral RNA or proviral DNA generally have a high 
analytical sensitivity, at least in the pre-seroconversion phase of the infection (de 
Andrés et al., 2005). However, the complexity of many of these assays limits their 
value in large scale studies or in less than fully-equipped laboratories. Extramiana 
et al. (2002) have reported a simple PCR method, the se and sp of which are as 
good as or better than those of serological methods. Both the AGID and whole-
virus ELISA suffer from the variable quality and high production cost of the viral 
antigen used, and the sensitivity of AGID is considered insuffi cient as a gold stand-
ard for the serology of SLRV infections (Saman et al., 1999). The reported se of 29 
AGID tests for SRLV antibodies, relative to ELISA, was on average 65.3% (de Andrés 
et al., 2005). More sensitive and stable ELISA assays employing monoclonal anti-
bodies (Houwers and Schaake, 1987) or recombinant viral proteins and peptides 
(Kwang and Torres, 1994; Saman et al., 1999) have been developed. Saman et al. 
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(1999) reported a sensitivity of 99.4% and specifi city of 99.3% relative to immuno-
(Western) blotting. A sensitive competitive-inhibition ELISA developed for the 
diag nosis of CAEV infections has also been successfully applied to the diagnosis of 
MVV infections (Herrman et al., 2003). The authors quote 98.6% se and 96.9% sp 
for their test in relation to immunoprecipitation. Commercial test kits for detect-
ing antibodies against MVV are available (for example ELISA Maedi–Visna / CAEV, 
Pourquier Institute, France), but exact se or sp fi gures have not been reported for 
the kit. The ELISA techniques are also applicable to antibodies in milk, but a lower 
sensitivity would be expected, since the levels of lentivirus antibodies in milk are 
substantially lower than in serum (Knowles et al., 1994). 
2.2 Comparative epidemiological aspects of the diseases
2.2.1 Occurrence of the infection / disease
BVD
BVD is present in most cattle-raising countries of the world (Lindberg, 2002). The 
OIE Handistatus statistics for Europe (Handistatus, 2004a) disclose that the infec-
tion is present in each country that has sent in a report, with the exception of 
Iceland. Based on the detection of antibodies against BVDV either in BTM or in 
sera of individual animals, the prevalence of infected herds in individual countries 
most often ranges from 70% to 100% (Edwards et al., 1987; Niskanen et al., 1991; 
Braun et al., 1997). The prevalence of herds with PI animals has ranged from 15% 
to 45% (Houe, 1995; Frey et al., 1996). The Scandinavian countries are an excep-
tion; after ten years of control and eradication programmes the seroprevalence 
among herds in each country is below 10% (Valle et al., 2005; Hult and Lindberg, 
2005; Veterinaer institut, 2004). 
IBR
The infection appears prevalent in most cattle-raising countries (Straub, 2001). The 
OIE Handistatus statistics for Europe (Handistatus, 2004b) disclose that the infec-
tion is present in the majority of the countries that have sent in a report, with 
the exception of Iceland and the EU Member States to which the additional guar-
antees for IBR apply (Austria, Denmark, Finland, Germany and Sweden; Decision 
2004 / 558 / EC). Switzerland is also considered to be free of infection (Ackermann 
and Engels, 2005), although the Handistatus statistics claim that it was positive in 
2004. 
In Europe the prevalences before control and eradication campaigns have been de-
scribed as variable to high, or in some cases quantitatively; e.g. 62–65% in Belgium, 
13–79% in Hungary, 62–85% in Italy, 40% in the Netherlands in dairy cattle, and 20–
38% in Poland (Ackermann and Engels, 2005; Boelaert et al., 2000; Tekes et al., 1999). 
Bulk-tank milk surveys in England and Wales revealed that 69% of dairy herds had an-
tibodies against BHV-1 (Paton et al., 1998), while in the Netherlands the correspond-
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ing fi gure was 84% (van Wuijckhuise et al., 1998). Of the Scandinavian countries, 
additional guarantees apply to Denmark and Sweden. Norway has been recognized 
as free of IBR since 1994 (Anon., 2003) and Sweden since 1998 (Danielsson, 2003).
EBL
Serological surveys have revealed that BLV infection is widely disseminated 
throughout the world, with high prevalence rates in North and South America, 
Africa, Asia and Australia (Hopkins and DiGiacomo, 1997). In Europe, offi cial EBL-
free status has been established for 14 EU Member States, and for several regions 
of Italy (Decision 2004 / 320 / EC). According to the OIE Handistatus statistics (Hand-
istatus, 2004c), the last reported occurrence of EBL was at least 7 years before the 
report from 2004 in 4 countries (Andorra, Cyprus, Czech Republic and Georgia). 
Nationwide surveys of EBL seroprevalence in other European countries are not in 
the public domain. The herd-level seroprevalence in the US has been estimated as 
85–90% (Wells et al., 1998), which is similar to that occurring, for example, in Ar-
gentina (Trono et al., 2001). Of the Scandinavian countries, Denmark and Sweden 
are offi cially free of EBL, while in Norway the last seropositive cow was detected in 
a small dairy herd in 2002 (Anon, 2003).
MV
MV occurs worldwide, with the exception of Iceland (Pålsson, 1985), New Zealand 
and Australia (Greenwood et al., 1995). Some of the other European countries be-
sides Iceland may be considered free according to the OIE defi nition (< 1% of herds 
infected with 99% probability) (quoted by Peterhans et al., 2004). However, the 
OIE Handistatus statistics (Handistatus, 2004d) claim that there are 11 countries 
among the 42 listed where the disease has never been reported; in four of these 
the disease is not even notifi able. Only few studies have reported actual country-
level prevalences of maedi–visna among sheep fl ocks. The slightly outdated report 
of Simard and Morley (1991) quotes a fi gure of 63% from 286 fl ocks in Canada hav-
ing at least one seropositive animal, with a mean prevalence of 12% within fl ocks, 
while Kita et al. (1990) report that all of the 18 fl ocks of sheep tested in Poland 
were infected, with a range of within-fl ock serological prevalence from 1.2% 
to 45.9%. More recently, Schaller et al. (2000) found only 9% from 226 fl ocks of 
breeding associations in Switzerland to be antibody-positive for maedi–visna virus. 
Of the Scandinavian countries, 35 MVV antibody positive sheep fl ocks were found 
in Norway in 2002 (Anon, 2003). Occasional sheep health control serum samples 
were positive for MVV antibodies both in 2002 and 2003 in Denmark (Veterinaer-
institut, 2004) and in Sweden (Jordbruksvärket, 2004).
2.2.2 Intrinsic determinants of the hosts
The intrinsic determinants of the hosts, pertinent to development the diseases, 
are compiled from Radostits et al. (2000), Murphy et al. (1999) and Timoney et al. 
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(1988) for all the diseases, and further from Lindberg (2002), Walz et al. (2001) 
and Bolin and Ridpath (1995) concerning BVD, from Cho et al. (2002), Schuh et al. 
(1992), Acker mann et al. (1990), and Miller and Maaten (1987) concerning IBR, from 
Petukhov et al. (2002), Johnson and Kaneene (1991), Bernoco and Lewin (1989) 
and Burny et al. (1980) concerning EBL, and from Blacklaws et al. (2004), Straub 
(2004) and Pepin et al. (1998) concerning MV, and are presented in Table 1.
2.2.3 Host–agent relationship 
Data pertinent to the host – disease agent relationship are compiled from Radostits 
et al. (2000), Murphy et al. (1999) and Timoney et al. (1988) for all the diseases, and 
further from Polak and Zmudzinski (2000), Houe (1999) and Brownlie et al. (1987) 
concerning BVD, from Thiry et al. (2005), Hage et al. (2003), and Tikoo et al. (1995) 
concerning IBR, from Monti and Frankena (2005), Licursi et al. (2002), Willems et al. 
(1993), and Mammerickx et al. (1987) concerning EBL, and from Pepin et al. (1998), 
Clements and Zink (1996) and Bird et al. (1993) concerning MV, and are presented 
in Table 2.
Table 1 Intrinsic determinants of the hosts pertinent to the development of the diseases
 Diseases 
Determinants BVD  IBR EBL MV 
Effect of age on susceptibility1 N Y, 12 N N 
Association of age with severity of disease1 Y, 2 Y, 2 A, 3 A, 3 
Typical age of clinical manifestation, years 1–3 0,5–3 4–8 > 2 
Breed predisposition2 1 1 1 2 
Effect of gender on susceptibility1 N F, 1 N N 
Effect of gender on clinical manifestation1 N F, 1 N N 
Impact of gestation or parturition on
 propagation of disease2 3 1 1 0 
Effect of immunological status  
 Duration of maternal immunity, months 3–93 2–4 1–3 3–6 
 Immunity after infection, years > 3 > 3 –4 – 
 Protection afforded by vaccination2 1 2 U – 
1 young (Y) / adult (A), or male (M) / female (F). If predisposition exists, the more affected age or gender 
is indicated. N = no predisposition
2 scale: 3, major; 2, signifi cant; 1, minor or incomplete; 0, insignifi cant or non-existent; U, possible but 
signifi cance unknown
3 non-PI animals   
4 information not available or not relevant
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2.2.4 Sources and transmission of the disease agents
The sources of the agent during infection and the principal means of transmission 
are compiled from Lindberg (2003), Rossmanith et al. (2001), Bitsch et al. (2000), 
Lindberg and Alenius (1999) and Kommisrud et al. (1996) concerning BVD, from 
Turin et al. (1999), Mars et al. (1999), and Vonk Noordegraaf et al. (1998) concern-
ing IBR, from Meas et al. (2002), Hopkins and DiGiacomo (1997), Sargeant et al. 
(1997a) and Johnson and Kaneene (1991) concerning EBL, and from Peterhans et 
al. (2004), Blacklaws et al. (2004), and Preziuso et al. (2004) concerning MV, and are 
presented in Table 3.
2.2.5 Extrinsic determinants of the diseases
The major extrinsic determinants, pertinent to development the diseases, are cli-
mate, soils and man (Putt et al., 1988). The fi rst two can interact in a variety of ways 
and affect the environment of the host and possible vectors. Climates that neces-
sitate indoor housing during the winter months predispose the closely-confi ned 
animals to spreading of the agents, especially via the respiratory route. This has 
been experimentally demonstrated for BVDV and BHV-1 (Mars et al., 1999), and 
observed for MVV (Blacklaws et al., 2004). Temperate or cold climates may also en-
hance the survival of the agent in the environment. The possibility of vector trans-
Table 2 Host–disease agent relationships in the diseases
 Diseases 
Relationships BVD IBR EBL MV 
Length of latent period, days 4–9 2–4 10–14 > 14 
Length of incubation period 6–9 d1 2–6 d1 > 3 y1 > 1 y1 
Length of period of communicability, days 10–14 14–70 lifelong lifelong
  / lifelong2  / variable3 
Length of carrier state, days 
 True carrier lifelong2 lifelong lifelong lifelong 
 Incubatory carrier < 3 < 3 lifelong lifelong 
 Convalescent carrier < 5 –4 – – 
Importance of antigenic variation5 
 Within host 0 / 22 0 0 2 
 Within population 2 1 1 2 
1 d, days; y, years
2 persistently infected (PI) animals
3 stress-induced intermittent shedding
4 not applicable
5 scale: 3, major; 2, signifi cant; 1, minor or incomplete; 0, insignifi cant or nonexistent
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Table 3 Sources and means of transmission of the disease agents
 Diseases
Sources and transmission BVD1 IBR1 EBL1 MV1 
Sources
 Main or major sources Secretions / Respiratory Lympho- Colostrum / 
 serum secretions cytes milk   
In blood 
 Minor sources Excretions Semen Colostrum Respiratory
    secretions  
Vertical transmission
 Germ line   0 0 0 0 
 Intrauterine or transplacental 3 1 1 0 
Horizontal transmission
 Live animal trading 3 3 2 3 
 Direct contact between animals 
  Ingestion of colostrum or milk 0 / 22 0 2 3 
  Respiratory or oral route 3 3 1 2 
  Venereal 0 2 0 0 
 Indirect contact between animals 
  Embryo transfer 1 1 0 U 
  Environmental (e.g. pastures)   2 1 0 1 
  Invertebrate vector 0 0 1 0 
  Airborne U 1 0 0 
  Fomites 1 0 0 0 
  Iatrogenic or other human 
   Through animal products 
    (serum, semen) 1 / 22 1 1 U 
   Mechanical (needles, 
    rectal palpation) 0 1 3 0 
Other domestic or wild species 
 as reservoir U 0 0 2 
1 scale: 3, major; 2, signifi cant; 1, minor or occasional; 0, insignifi cant; U, possible but signifi cance unknown
2 transiently infected / PI animal
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mission is only associated with BLV (Johnson and Kaneene, 1991); however, this is 
probably only a minor or insignifi cant route (Hopkins and DiGiacomo, 1997). 
The determinants due to man include the extensive trade of animals and products 
of animal origin, providing opportunities for the agents to spread. This is shown 
especially unequivocally with MV (Straub, 2004). On the other hand, the use of 
vaccines and drugs and the implementation of control measures and eradication 
programmes seek to counter the inadvertent spread and proliferation of the in-
fections. 
Information on other infections or diseases as specifi c extrinsic determinants to ad-
vance the present diseases is scarce. The cp-type BVDV superinfection is required to 
produce the mucosal disease in PI animals infected with ncp-BVDV (Kummerer et 
al., 2000). Coinfection with bovine respiratory syncytial virus (BRSV) and ncp-BVDV 
produced a synergistic depression on alveolar macrophage functions (Liu et al., 
1999). A novel bovine lymphotropic herpesvirus (Rovnak et al., 1998) and bovine 
immunodefi ciency virus (BIV, Meas et al., 2002) appeared to be possible cofactors 
for BLV infection. MVV replication was enhanced in sheep coinfected with sheep 
pulmonary adenomatosis virus (Dawson et al., 1990).
2.3 Control and prevention measures against the diseases
2.3.1 Individual and herd levels
Measures applied to control and limit the spread of the infections and diseases on 
a low level are compiled from Greiser-Wilke et al. (2003) and Lindberg and Ale nius 
(1999) concerning BVD, from Hage et al. (2003), van Schaik et al. (2002), Graat et al. 
(2001) and Vonk Noordegraaf et al. (1998) concerning IBR, from Pence et al. (2004), 
Danielsson (2003) and Hopkins and DiGiacomo (1997) concerning EBL, and from 
Knight (2004), Houwers et al. (1987) and Cutlip and Lehmkuhl (1986) concerning 
MV, and are presented in Table 4.
2.2.2 Regional and national levels
Measures applied to control and limit the spread of the infections and diseases on 
medium level are compiled from OIE statistics (Handistatus, 2004a), Sandvik (2004), 
Lindberg (2003), and Bitsch et al. (2000) concerning BVD, from OIE statistics (Hand-
istatus, 2004b), Vonk Noordegraaf et al. (2004), Holzhauer et al. (2003) and Pospísil 
et al. (1996) concerning IBR, from OIE statistics (Handistatus, 2004c), Danielsson 
(2003), Hayes and Burton (1998), DiGiacomo (1992) and Gottschau et al. (1990) con-
cerning EBL, and from OIE statistics (Handistatus, 2004d), Peterhans et al. (2004), 
Houwers et al. (1987) and Biront and Deluyker (1985) concerning MV, and are pre-
sented in Table 5.
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2.3.3 International (EU) level
The European Union subsidizes animal disease eradication and moni toring pro-
grammes that aim at eliminating endemic diseases in, and preventing the spread 
of exotic diseases into the community. The diseases covered include IBR in AI and 
embryo units and other types of enterprise, EBL and MV (EU, 2005). The measures 
in the programmes include a wide range of activities such as vaccination, testing of 
animals, compensation for slaughtering or culling, and treatment. The EU legisla-
tion pertinent to BVD, IBR, EBL and MV are reviewed below, in subchapter 4.1.2.
Control 
measures
Diseases
BVD IBR EBL MV
On indi-
vidual level
Vaccination Vaccination of 
both sero negative 
and sero positive 
animals
Use of disposable/
sterile instruments
Separation of 
offspring from 
infected dam
No feeding of milk 
or colostrum from 
EBL-suspected 
herd or herd of 
unknown status, 
unless pasteurized
Separation of 
offspring from 
infected dam
Segregation of 
infected animals 
from non-infected
On herd 
(fl ock) level    
Testing of animals 
for PI-status, posi-
tive culled
No purchase of 
antibody-positive 
pregnant dams
Herd certifi cates 
updated with 
annual retesting
No contacts with 
un-certifi ed ani-
mals (no common 
pastures, visits to 
exhibitions, etc)
All animals > 6 
mo of age tested 
for antibodies 
seropositive sepa-
rated or culled, 
seronegative 
tested repeatedly 
every 3 mo,           
 or
All animals 
vaccinated repeat-
edly; calves reared 
In isolation and 
tested at least 
twice, seronega-
tive stock raised in 
separation
 or
All animals 
removed premises 
cleaned and 
dis infected and 
re stocked with 
IBR-free herd
Elimination of all 
BLV-antibody or 
antigen positive 
cattle. or at 
least isolation of 
seropositives
Testing herd 
additions retesting 
after 60 d
Annual testing 
of the herd for 
BLV antibodies 
and check of herd 
records
Slaughtering 
entire fl ock
 or
Slaughtering sero-
positive animals 
and their progeny
Regular testing of 
all animals in the 
fl ock
Restrictions 
on contacts to 
uncertifi ed fl ocks, 
or animals quaran-
tined until shown 
sero negative
Table 4 Infection or disease control measures on individual and herd levels
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The OIE Terrestrial Animal Health Code (web version: OIE, 2005) sets conditions for 
qualifi cation for and maintenance of country and region freedom from IBR and 
EBL, as well as requirements for the import of live animals with respect to IBR, EBL 
and MV. The requirements extend to the import of semen with respect to IBR and 
EBL. The conditions are presented in Table 6.
Control 
measures
Diseases
BVD IBR EBL MV
On 
regional 
and 
national 
levels
Describing the 
structure of the 
industry in suf-
fi cient detail
Employing reliable 
diagnostic tests
Prevalence of 
BVDV infection 
determined in 
comprehensive 
surveys
Screening for the 
infection
Launching of con-
trol programs to 
reduce prevalence
Educating herd 
owners and other 
stake holders on 
biosecurity issues
Animal disease  
legislation up-
graded to support 
eradication, e.g. 
on animal trade or
AI centre proceed-
ings
Authorization of 
use of vaccines
Precautions at 
the border and 
movement control 
inside the country
Prevalence 
or absence of 
BHV-1 infection 
determined in 
comprehensive 
surveys
Screening for the 
infection
Notifi able disease
Launching compul-
sory eradication 
campaign based 
on modelling the 
minimal surveil-
lane (high initial 
prevalence)
Modifi ed stamping 
out
Animal disease  
legislation 
upgraded to sup-
port eradication, 
e.g. restrictions 
on trade of sero-
positive animals
Authorization of 
use of vaccines
Precautions at 
the border and 
movement control 
inside the country
Educating various 
professionals com-
ing into contact 
with dairy and 
beef herds, on EBL 
biosecurity issues
Advisory services 
provided to cat-
tle owners on 
prevention of BLV 
infections
Screening for the 
infection
Notifi able disease
Identifying most  
suitable test kits 
for serum and 
bulk-tank milk 
screening
Launching of 
control and 
eradication  
programs based 
on approach “test 
and slaughter”
 or
“test and segre-
gate”
 or
“test and imple-
ment  corrective 
management”
Precautions at 
the border and 
movement control 
inside the country
Establishing 
national SRLV 
reference labora-
tory 
Testing for anti-
bodies performed 
only in accredited 
laboratories
Prevalence of 
SRLV:s determined 
in comprehensive 
surveys
Sreening for the 
infection
Notifi able disease
Launching of con-
trol programs to 
reduce prevalence
Animal disease  
legislation up-
graded to support 
eradication
Modifi ed stamp-
ing out
Precautions at 
the border and 
movement control 
inside the country
Table 5 Infection or disease control measures on regional and national levels
OIE Terres-
trial code
Diseases
BVD IBR EBL MV
Qualifi -
cation
Not 
specifi ed
Disease or suspicion 
of it notifi able
No animal vaccinated 
against IBR / IPV for at 
least 3 yr
At least 99.8% of 
herds qualifi ed as free
All LSA-like tumors 
reported to veterinary 
authority, and exam-
ined in competent 
laboratory
If LSA confi rmed or 
can not be ruled out, 
the herds of origin 
are traced and all 
cattle over 2 yr of age 
tested
At least 99.8% of 
herds qualifi ed as free
Not specifi ed
Mainten-
ance
Not 
specifi ed
Annual survey with 
suffi cient sample 
to reveal > 0.2% 
prevalence with 99% 
confi dence
Annual survey with 
suffi cient sample 
to reveal > 0.2% 
prevalence with 99% 
confi dence
Not specifi ed
Require-
ments for 
im port
   
Not 
specifi ed
Imported animals 
show no clinical signs 
of IBR / IPV on day of 
shipment
 and
Come from an IBR / IPV 
free herd
 or
Were kept in quaran-
tine station for the 
30 d prior to ship-
ment, and tested 
negative twice with 
an interval of at least 
21 d
Or if destined to not 
qualifi ed herd:
Showed no clinical 
signs and were vaccin-
ated with in activated 
vaccine 1–6 mo prior 
to shipment
Imported fresh and 
frozen semen from 
a donor bull in an 
IBR / IPV free herd
Frozen semen: the 
bull kept in isolation 
for period of collec-
tion and 30 d after, 
and tested negative 
at least 21 d after the 
collection
Imported animals 
come from a herd in 
which:
No clinical or patho-
logical evidence or 
positive
EBL test result within 
preceding 2 yr
 and
All animals > 2 yr of 
age tested negative 
twice during preced-
ing year, at an interval 
of at least 4 mo
The imported animals 
tested negative for 
EBL within 30 d prior 
to shipment
Imported semen from 
a donor bull in an 
EBL-free herd
The bull tested nega-
tive for EBL twice, 
at least 30 d before 
and 90 d after semen 
collection
Imported animals 
showed no clinical 
signs on day of ship-
ment
 and
Animals > 1 yr of age 
tested negative for 
MV during the 30 d 
prior to shipment
Animals come from 
fl ocks where MV was 
not diagnosed during 
preceding 3 yr
 and 
which had had no 
additions from fl ocks 
of inferior status dur-
ing the same period
Table 6 Conditions set by the OIE for country and region freedom from disease
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2.4 Attempts to eradicate the diseases, essential measures 
and perceived problems in eradication
2.4.1 BVD 
The only country-wide control and eradication schemes for BVD have been launched 
in Scandinavia. These programmes, initiated in the early 1990s, have reduced the 
BVD prevalence in each country below 10%, but the struggle with the “tail” of the 
occurrence will probably take longer than once expected. However, the Shetland 
Islands (UK) did initiate a BVD control scheme simultaneously with the Scandina-
vian countries in 1994, and by January 1997 the last scheduled young stock tests 
were negative, indicating that the islands had been successfully cleared of BVD. 
Unfortunately, a dam carrying a PI foetus was introduced to the islands in 1998, 
which resulted in 21 new infected herds and meant that a new round of BVDV 
clearance had to be started (Sandvik, 2004). Regionwide eradication programmes 
have been initiated, for instance, in Lower Austria (Rossmanith et al., 2001), Ger-
man Lower Saxony (Greiser-Wilke et al., 2003), the Rome province of Italy (Ferrari 
et al., 1999), the Bretagne area of France (Joly et al., 2005), the Netherlands (Mars 
et al., 2005) and Slovenia (Grom and Barlic-Maganja., 1999). The BVD prevalences 
in each case have been substantially reduced from the original levels. 
The Lower Austrian programme, initiated in 1996, was designed according to the 
Swedish programme (Alenius et al., 1997), highlighting the central role of the iden-
tifi cation and elimination of PI animals (Rossmanith et al., 2001). An important risk 
factor for BVDV transmission in Austrian local conditions is communal grazing, 
where susceptible pregnant cattle from several herds may be mixed with unrecog-
nized PI animals. The programme is based on four principles: 1) information and 
education for all groups involved, 2) dividing the herds into presumably non-in-
fected and infected, 3) the protection of non-infected herds and 4) systematic dis-
ease clearance in infected herds (Rossmanith et al., 2005). An Austrian federal law 
was laid down in 2004 committing all herd owners to eradicate BVDV according to 
the Scandinavian scheme (Anon., 2004).
A Federal guideline for the control of BVD was issued in Germany in 2000 (Moen-
nig and Greiser-Wilke, 2003) and some Federal States have even provided addi-
tional regulations concerning compensation for PI animals and additional costs. 
For example, German Lower Saxony (Niedersachsen), where the seroprevalence of 
BVDV infection is high, has a programme with the following main points (Greiser-
Wilke et al., 2003):
(1) Voluntary participation; 
(2) Identifi cation of PI animals by testing all stock < 3 years of age in the participat-
ing herds twice (at least 14 days apart) for the antigen, and culling those posi-
tive in both tests;
(3) Systematic vaccination of female offspring;
(4) Applied biosecurity measures, including trade only with herds of equivalent 
status.
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In a defi ned area of the Rome province of Italy a programme to eradicate BVD 
was launched in 1997 (Ferrari et al., 1999). The programme makes use of the se-
rum samples collected biannually from every bovine animal > 1 year of age as part 
of brucellosis and leucosis eradication programmes. The voluntary BVD eradication 
programme is based on three measures:
(1) Immediate removal and slaughter of PI animals;
(2) Movement control by submitting blood samples of newly introduced animals 
to serological and virological investigations;
(3) Serological and virological control of all animals sold to other reproduction 
units if the herd has not yet acquired BVD-free status.
Vaccines are used in the programme only if specifi cally requested by the herd 
owners.
The Scandinavian programmes have several common features. A strict non-vacci-
nation policy is observed in each, which allows identifi cation of infected herds in 
large-scale screenings based on the detection of antibodies. In outline the eradica-
tion programmes are comprised of four steps (Sandvik, 2004; Greiser-Wilke et al., 
2003):
(1) Pinpointing the infected herds by repeated nationwide surveys of herds. Dairy 
herds are moni tored through BTM sample testing. Alternatively, sera from a 
limited number of animals representing all epidemiological groups of the herd 
are tested for antibodies against BVDV (“spot testing”). 
(2) Certifi cation and moni toring of non-infected herds; certifi cations updated reg-
ularly by retesting. 
(3) Virus clearance of infected herds, using high BVDV antibody levels in ELISA 
tests as an indication of an active infection, and individually testing all animals 
> 2–3 month of age, or milk of primiparous cows and sera of young stock in 
suspected herds, for antibodies. Virus isolation is performed from each animal 
displaying a low level of antibodies, and all positive animals are culled. Follow-
up testing of the herd has to be performed at regular intervals until all calves 
at six months of age are seronegative.
(5) Establishing prophylactic measures and biosecurity guidelines to prevent rein-
fection. 
The Slovenian programme (Grom and Barlic-Maganja, 1999) focuses on breeding 
selection herds, breeding herds for young bulls, the herds of origin of these bulls 
and AI stations. The programme is based on blood-sampling from entire herds. 
This labour-intensive approach is considered to be the only method giving reliable 
information on the seroprevalence of BVDV infection within each herd, and ena-
bling immediate identifi cation of PI animals among the seronegative ones. Bovine 
breeding herds in Slovenia have never been vaccinated against BVDV infection.
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Essential measures and perceived problems in eradication
Essential measures Regular testing of all herds, locating the herds most likely to 
have an active infection and removing PI animals from them, and strict control of 
livestock trade associated with the risk of PI animals. Moennig et al. (2005) pro-
pose that the removal of PI animals, moni toring of the health status in combina-
tion with systematic vaccination might be an alternative acceptable in Europe out-
side of Scandinavia.
Perceived problems Insuffi cient sensitivity of antigen-ELISA tests to detect PI ani-
mals, especially in the presence of maternal antibodies (Rossmanith et al., 2001). 
Furthermore, the sensitivity of the tests to detect the virus in the semen of acutely-
infected bulls is not satisfactory (Sandvik, 2005). The current vaccines are not 
marker vaccines and do not convey solid protection to the foetus (Grooms, 2004).
2.4.2 IBR 
IBR has successfully been eradicated from several European countries or regions 
(Austria, Denmark, Norway, Sweden and Switzerland, and the province of Bolzano 
in Italy; Decision 2004 / 558 / EC). In each case, eradication was based on the test-
ing of animals for antibodies against BHV-1, culling or separating the seroposi-
tive animals from the seronegative ones and subsequent restocking with only se-
ronegative stock. Vaccination was not employed in these countries. This rigorous 
“selection” approach is considered unfeasible in many other European countries 
(Belgium, Hungary, the Netherlands, and the province of Veneto in Italy) where 
the prevalence of the infection is high. The latter countries or regions are basing 
their IBR control on large-scale vaccination with marker vaccines. In Germany a few 
states are applying the “selection” approach, while the majority are vaccinating. 
Regional voluntary eradication programmes have also been launched in France 
and the Republic of Ireland (Brownlie, 2005).
The control and eradication scheme of Belgium has been divided into three phases. 
The fi rst consisted mainly of voluntary vaccination, classifi cation of the herds and 
evaluation of virus spread; this phase was completed in 1999–2000 (Vanopden-
bosch and Kerkhofs, 2004). The second, current phase includes compulsory vaccina-
tion, culling or vaccination of infected animals and strict control of transfers. The 
objectives of this phase are the ending of virus spread, and eventual ending of vac-
cination. The third phase will include qualifi cation of herds after the end of vac-
cination, compulsory culling of infected animals, and strict zoosanitary measures 
and control of stock movement. Transition to phase three will be based on the re-
sults of yearly random sampling and serology (Limbourg et al., 2002).
Tanyi and Varga (1992) presented guidelines for the eradication of IBR in Hungary. 
They considered three courses of action: the separation and vaccination of infected 
animals in herds, eradication by generation shift and eradication by total herd 
replacement. Regional voluntary programmes are active in Hungary at present 
(Brownlie, 2005).
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In the province of Veneto, Italy, it is recommended that the herds are fi rst classi-
fi ed into two categories on the basis of the seropositivity level. Vaccination with a 
live marker vaccine is to be used only in herds having a high seropositivity, while 
the “test and remove” concept should be used in the (majority of) low seropositiv-
ity herds (Nardelli et al., 1999).
In the Netherlands the best strategy on the basis of data available so far, together 
with a model study, consists of three measures (Franken, 2004):
(1) Obligatory vaccination with a live marker vaccine according to a programme, 
the vaccinations being recorded by the animal health service. Herds comply-
ing with or fi tting in a given set of conditions may receive fi nancial compensa-
tion;
(2) Elimination of the last gE positive (infected) animals;
(3) Completion of the vaccination programme (estimated to be in 2005).
Essential measures and perceived problems in eradication
Essential measures A live marker (gene-deleted) vaccine and a diagnostic test to 
differentiate between vaccinated and infected animals in countries or regions of 
high prevalence; the separation and eventual culling of seropositive animals; strict 
control on external contacts between herds.
Perceived problems Failure to easily detect seronegative latent carriers (Lemaire 
et al., 2000) could pose a threat to IBR-free herds and AI centres. The tests for an-
tibodies against BHV-1 in BTM samples will only detect herds in which the BHV-1 
prevalence is greater than 10% (Hartman et al., 1997) or 20% (OIE, 2004), so that 
BTM-negative herds need some confi rmatory test of their infection status. In coun-
tries where the majority of dairy herds are already free or BTM-negative this means 
considerable expenditure. 
2.4.3 EBL
Enzootic bovine leukosis has successfully been eradicated from several European 
Union countries: Belgium, Denmark, Germany, Spain, France, Ireland, Luxembourg, 
the Netherlands, Austria, Sweden and the United Kingdom, and many regions or 
provinces of Italy (Decision 2004 / 320 / EC). Jazbec et al. (1985) reported the eradica-
tion of EBL from Slovenia.
The identifi cation of infected animals either by haematological or serological 
methods, employing biosecurity measures such as raising young calves with colos-
trum and milk from only seronegative dams, and eventual culling of the seroposi-
tive animals, have formed the common approach in Europe, as well as in New York 
State of the United States (Brunner et al., 1997), Australia (Ross and Kirkland, 1993) 
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and New Zealand (Hayes and Burton, 1998). DiGiacomo (1992) reviewed and dis-
cussed the three successful approaches to eradicate BLV on the herd level: test and 
slaughter, test and segregate, and test and implement corrective management. 
The test and segregate approach has been used more frequently in North America 
than the other approaches (Shettigara et al., 1989; DiGiacomo, 1992). The respec-
tive advantages and disadvantages of these approaches, and the effi ciency in erad-
icating the infection are:
– Test and Slaughter: The infection will be eliminated in months, whatever the 
initial prevalence. The approach can be exceedingly expensive if the initial 
prevalence is high. Reports of using this approach describe a reduction of prev-
alence from 11% to 4% in 6 months in 222 herds (Maas-Inderwiesen et al., 
1978), and from 10% to 2% in 12 months in 32 herds (Burki et al., 1983).
– Test and Segregate: Segregating the seropositive and seronegative stock into 
separate premises or locations will keep the latter free of infection (Kaja et 
al., 1884; Weber et al., 1987). Separating the two groups but housing them in 
the same premises may prevent the infection from spreading to the seronega-
tive group, but evidence for eventual eradication of the infection is inconclu-
sive (Johnson et al., 1985). Animals from the seropositive group will not be re-
moved prematurely but by natural attrition, which may take several years. 
– Test and Implement Corrective Management: The approach includes both sur-
veillance (testing) and measures to prevent the transmission of the virus. Rup-
panner et al. (1983) reported a reduction from 50% to 14% seroprevalence 
while Sprecher et al. (1991) were able to signifi cantly decrease the seropreva-
lence in all age cohorts, e.g. in the 181 days to parturition cohort from 44% to 
17% within three years. In both studies the measures focused on the preven-
tion of transfer of blood (lymphocytes) between cattle. In this approach there 
is no need to invest in separate housing, or to prematurely cull animals, but it 
requires a long-term commitment with repeated testing and vigilant mainten-
ance of the altered management.
Essential measures and perceived problems in eradication
Essential measures Elimination of BLV-seropositive animals from the herd with at 
least three consecutive tests for all animals, 3–6 months apart, and strict avoidance 
of blood (lymphocyte) contacts between animals.
Perceived problems The tests for antibodies against BLV in BTM will only detect 
herds in which the BLV prevalence is greater than 5% (Klintevall et al., 1991; Hayes 
and Burton, 1998). In large herds the prevalence may well remain below 5%. The 
length of the time from infection to seroconversion (57 d, 95% CI 49–75 d) may 
complicate the assessment of the time and route of transmission.
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2.4.4 MV
Iceland is the only European country that has defi nitely eradicated the disease 
(Pålsson, 1985). However, according to the OIE Handistatus statistics (Handistatus, 
2004d) the last reported clinical case of MV, for example in Ireland, had been in 
1986. An eradication programme had been carried out in this country in the 1970s 
and early 1980s (Guven, 1985). However, Ireland is not free of CAEV according to 
the OIE statistics. 
Control and eradication programmes for lentivirus infections have been estab-
lished or attempted in many other European countries: Belgium (Biront and De-
luyker, 1985), Denmark (Hoff-Jörgensen, 1985), France (Remond et al., 1985), the 
Netherlands (Houwers et al., 1987), Norway (Krogsrud, 1985; Dyrehelsetilsynet, 
2003), Sweden (SVA, 2003) and Switzerland (Scheer-Czekhowski et al., 2000). Sim-
ilar programmes or procedures are also active in North America (Knight, 2004; 
Menzies and Simard, 2001; Williams-Fulton and Simard, 1989). There are four com-
mon features to most of these programmes:
– Serological testing of all animals over 6 months of age;
– Segregating or culling of the seropositive animals and their progeny, or, in case 
the proportion of seropositive animals in the fl ock is high, stamping out the 
entire herd;
– All animals over 6 months of age are tested at 6 to 12-months intervals, and 
the seropositive animals removed. This testing is repeated until no new sero-
positive animals are detected in two annual tests;
– All replacement animals for the free herd must originate only from similar free 
herds – or the animals must be quarantined and shown to be seronegative with 
suffi cient testing.
Variations in the general scheme include delivery by Caesarean section or isolation 
at birth of the progeny from seropositive dams and heat-treating or pasteurizing 
of the dam’s colostrum and milk (Houwers et al., 1987). Restrictions are imposed on 
contacts with other herds on pasture or in animal shows, and the Norwegian pro-
gramme (Krogsrud, 1985) also has explicit restrictions on ram circle activity. Most 
programmes require regular follow-up testing even after attaining the free status, 
either of all animals or a representative sample of them.
Essential measures and perceived problems in eradication
Essential measures So far the only really effective measure for eradication on a 
national scale has been decisive stamping out in the Icelandic manner. The culling 
of seropositive animals and their progeny in a repeated testing scheme has been 
shown to be effective in clearing individual herds of the infection.
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Perceived problems Estimates for the mean time from infection to seroconver-
sion range from weeks to several months, and some animals may remain seronega-
tive (Sihvonen, 1981; Pepin et al., 1998). Some seropositive ewes may even become 
seronegative shortly after lambing as a result of depleting circulating antibody 
through the colostrum (Knight, 2004). The clearing of herds under control schemes 
which depend essentially on detecting seroconverted animals may hence be im-
peded.
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3 Aims of the study
The aims of the present thesis were to:
1 compile and review information presented in the literature concerning
• the aetiology and pathogenesis of four signifi cant viral infections and dis-
eases of domestic ruminants (I, III–V)
• the epidemiological aspects or features of these infections and diseases 
(I–V)
• the control and prevention measures applied against these infections and 
diseases (I–V)
• the attempts to eradicate these infections and diseases (I–V),
2 describe
• the legal and offi cial framework for control of the four infections and dis-
eases in Finland (II–V)
• the measures applied to control and eradicate these infections and diseases 
from Finland (I–V)
• the development in the situation of these infections and diseases in Finland 
(I–V)
3 assess the effi cacy of the measures applied in Finland employing the concept of 
the reproduction ratio of infections (R).
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4 The Finnish approach to control and prevention
4.1 Framework and measures
4.1.1 Pertinent domestic and EU legislation
General
The Animal Diseases Act (55 / 1980) with its later amendments (809 / 1992, 424 / 1994, 
1193 / 1996, 491 / 1997, 1000 / 1997, 398 / 1998, 804 / 1999 and 1000 / 1999), and the Ani-
mal Diseases Decree (601 / 1980) laid down on basis of the Act, with its later amend-
ment (117 / 1998), provide the general framework for the control and prevention 
of all animal diseases. The classifi cation of specifi c diseases according to their com-
municability, severity and other characteristics is given in Decision 1346 / 1995 of the 
Ministry of Agriculture and Forestry (MAF). This decision has been amended three 
times (532 / 1997, 136 / 1998 and 200 / 2004). The domestic legislation concerning con-
trol of animal diseases in intra-community trade and trade with third countries 
(foremost MAF Decrees 1338 / 96 and 655 / 2003, and decisions 572 / 95 and 1548 / 94, 
with their later amendments) are harmonized with the respective EU legislation. 
To complement the offi cial measures to prevent the import of animal diseases 
through trade the Association for Animal Disease Prevention (ETT ry) has issued 
standing instructions for import of animals, semen and embryos (ETT, 2004). Ob-
serving the instructions of this private association is voluntary, but the ETT member 
slaughterhouses, dairies, and egg packaging plants do not accept animals or prod-
ucts from animals imported in contravention of or neglecting the instructions. The 
“Domestic legislation” chapters below deal with the disease-specifi c statutes and 
other legislation such as overall health-control programmes in which the diseases 
are referred to. Although laid down in the disease-specifi c decrees and circulars, 
the actual control programmes and schemes are presented separately.
BVD
Domestic legislation Prior to May 2004 there was no specifi c domestic legisla-
tion for BVD. A new decree was laid down in 2004 to control this disease (MAF 
2 / EEO / 2004). The decree elevated the status of BVD to notifi able and cases of BDV 
must be reported monthly to the Department of Food and Health (earlier Veteri-
nary and Food) of the MAF. The new decree enables decisive actions to limit the 
spread of the infection. Specifi cally, a suspected or confi rmed BVD-positive herd is 
placed under restrictive measures that include mandatory reporting of the infec-
tion to the associated dairy and slaughterhouse, and to visitors whose entrance 
to the animal shed is unavoidable. Protective clothing and footwear must be pro-
vided to these visitors. Further, all the animals on the farm must be listed and 
accounted for, moving of the animals to or from the farm except to slaughter is 
prohibited, and contact with other cattle, sheep or goat farms must be prevented. 
The essential measure to eliminate the infection is culling all of the PI animals and 
their progeny less than 3 months of age, and subsequent follow-up between 4 and 
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12 months after the PI animals have been culled. Pending application by the owner 
of a PI animal, the authorities can order its slaughter at the partial expense of the 
state. Inspection visits, the taking of appropriate samples by the veterinarian and 
examination of the samples, pursuant to the decree, are also recompensed by the 
state. The district veterinarian is obliged to conduct an epidemiological investiga-
tion to identify the source of the infection and to trace the contact herds where 
the infection may have spread. The contact herds are also placed under restrictive 
measures if deemed appropriate, and the BVD situation is assessed. If goats, sheep 
or pigs are also kept on the farm the district veterinarian decides on the testing of 
these animals. The restrictive measures are withdrawn only either after the initial 
suspicion is shown to be unfounded, or the follow-up after culling of the PI ani-
mals has proved that there is no more active infection in the herd, or 30 days have 
passed after slaughter of all cattle and disinfection of the premises.
The MAF circular 3 / 93, laying down the health requirements for bovine semen, ne-
cessitated that bull calves to be sold to rearing stations and their herds of origin 
must be tested for antibodies against BVDV. The calves had to be retested at the 
rearing station and as bulls at the AI station at least once a year for BVDV anti-
bodies, with negative results. If a bull seroconverted while in the station the 
semen taken since the last seronegative result could not be used. The MAF decree 
6 / EEO / 2004 replaced circular 3 / 93. The requirements have been preserved except 
that if a bull seroconverts while in the station the semen taken since the last sero-
negative result can be used if it is tested for BVDV, with negative results.
EU legislation EU legislation does not contain BVD-specifi c directives or regula-
tions. Directive 2003 / 43 / EEC, the fourth amendment to Directive 88 / 407 / EC espe-
cially with respect to the animal health requirements applicable to intra-Commu-
nity trade and imports of semen of bovine animals, requires that the donor bulls be 
tested for both BVD virus antigen and antibodies against BVDV before and during 
the quarantine preceding movement to AI centres. The condition for entering the 
AI centre is that if seroconversion occurs during the quarantine the animals that 
are still seronegative are kept in quarantine until no seroconversions occur in the 
group for a period of three weeks. Seropositive animals are allowed entry to the 
AI centre. When in the centre, all the seronegative animals must be tested once a 
year for antibodies against BVDV. Should an animal seroconvert, every ejaculate of 
that animal collected since the last negative test shall either be discarded or tested 
for BVD virus antigen with negative results. 
IBR
Domestic legislation The control measures for IBR were laid down in the MAF 
circular 1 / 93. The disease is notifi able according to MAF decision 426 / 1993 and 
cases of IBR must be reported without delay to the Department of Food and Health 
(earlier Veterinary and Food) of the ministry. If IBR infection is suspected in a herd, 
all bovine animals of the herd must be tested for antibodies against BHV-1. A 
suspected or serologically confi rmed IBR antibody-positive herd is placed under 
restrictive measures that include the following: 
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–  Seropositive and clinically ill animals must be isolated to the extent possible 
from the other animals and kept indoors;
–  Bovine animals can only be transported from the farm for slaughter;
–  Delivery of bovine semen from the herd and the use of animals for natural 
mating are prohibited;
–  After the seropositive animals have been culled the stalls and appliances must 
be cleaned and disinfected with disinfectants that are active against viruses;
–  Unnecessary visits to the animal shed must be avoided and the use of protec-
tive clothing and footwear in the shed is mandatory.
No restrictions are imposed on the use of milk or its delivery to the dairy.
The restrictive measures can also be based on results from the annual bulk-tank 
milk surveillance. Pending application by the owner and the recommendation of 
the district veterinarian, the authorities can order the slaughter of seropositive 
animals at the partial expense of the state. The clinical examination of the entire 
herd and taking of the appropriate samples by the veterinarian, pursuant to the 
decree, are also recompensed by the state. The municipal veterinarian is obliged to 
conduct an epidemiological investigation to map the spread of the infection, ac-
cording to instructions from the district veterinarian. The restrictive measures are 
only withdrawn after seropositive animals have been culled and the other animals 
tested negative twice, one month after the culling and then four months after the 
fi rst test, at the earliest. If goats, sheep or pigs are also kept on the farm the district 
veterinarian decides on the testing of these animals.
The compulsory health control program (MAF 16 / EEO / 1997) for deer farms re-
quires that all the deer over 6 months of age on farms that sell animals must be 
examined once for antibodies against BHV. Seropositive animals must be isolated 
and the veterinary authorities decide how they are dealt with.
The Veterinary Department letter 1104 / 143 (1981) concerning health moni toring 
programme for AI bulls stipulated that an AI bull had to be tested for antibodies 
against BHV-1 before entering the AI station, and before sending it from the sta-
tion to slaughter. The MAF circular 3 / 93 replacing 1104 / 143 and laying down the 
health requirements for bovine semen necessitated that bull calves to be sold to 
rearing stations and their herds of origin must be tested for antibodies against 
IBR / IPV. The calves had to be retested at the rearing station and as bulls at the AI 
station at least once a year for IBR antibodies, with negative results. If a bull sero-
converted while in the station the semen taken since the last seronegative result 
could not be used. The MAF decree 6 / EEO / 2004 replaced circular 3 / 93, but the re-
quirements have been preserved. The MAF circular 1 / 94, laying down the health 
requirements for bovine embryos, requires that the herd of origin of the donor an-
imal must have been free of IBR / IPV for the previous 6 months.
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EU legislation Annex E (II) to Directive 64 / 432 / EEC, last amended in 1997 (Direc-
tive 97 / 12 / EC), lists IBR among the diseases for which national control programmes 
may be approved and additional guarantees requested. IBR is also a disease for 
which the control and eradication programmes in both AI and embryo units and 
other types of enterprise may receive a fi nancial contribution from the Community 
(latest Decision 2004 / 450 / EC, Annex I Part A). Finland has since 1994 been one of 
the IBR-free countries to which the additional guarantees for IBR apply (latest De-
cision 2004 / 558 / EC, Annex II). The guarantees include:
– Bovine animals for breeding and production, originating from countries or re-
gions to which the guarantees do not apply, and destined to Finland, must 
come from a holding on which no clinical or pathological evidence of IBR has 
been recorded for the past 12 months;
 
– they must have been isolated for 30 days immediately prior to movement and 
all bovine animals in the same facility must have remained free of clinical signs 
of IBR during that period;
– they and other bovine animals of the isolation facility must be tested with 
nega tive results for antibodies against BHV-1 not earlier than 21 days after 
their arrival at the isolation facility; and
– they must not have been vaccinated against IBR. Bovine animals for slaughter 
must be transported directly to the slaughterhouse.
Directive 2003 / 43 / EEC, the fi fth amendment to Directive 88 / 407 / EC laying down 
the animal health requirements applicable to intra-Community trade and imports 
of semen of bovine animals, requires that the donor bulls be tested for antibodies 
against BHV-1 (whole virus) both before the quarantine if the animals do not come 
from an IBR-free herd, and during the quarantine with negative results. If any ani-
mals test positive during the quarantine, these animals shall be removed immedi-
ately from the quarantine station and the other animals in the group retested no 
less than 21 days after the removal of the positive animals, with negative results. 
The bulls are to be tested at least once a year for antibodies against BHV-1 (whole 
virus) with negative results. If the result is positive the animal must be isolated and 
the semen collected since the last negative test may not be subject to intra-commu-
nity trade. Decision 94 / 113 / EC, amending Directive 89 / 556 / EEC on animal health 
conditions governing intra-Community trade in and importation from third coun-
tries of bovine embryos, requires that the donor animal must come from a herd in 
which no animal has shown signs of IBR / IPV during the previous 12 months.
EBL
Domestic legislation The earliest government decision concerning the control 
of EBL was given in 1966 (MAF 242 / 1966). This decision outlined the haemato-
logical screening of herds based on leukocyte counts (Bendixen, 1965). Subsequent 
MAF circulars (168 / 1976, 173 / 1979 and 183 / 1980) refi ned and expanded upon 
the control measures. The current MAF circular 2 / 1993 contains a programme 
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(part 8) for attaining herd-level freedom from EBL. This part was removed in 1997 
(MAF15 / EEO / 97) when mainland Finland was offi cially declared free of EBL. EBL 
is a notifi able animal disease according to MAF decision 426 / 93 and cases of EBL 
must be reported without delay to the Department of Food and Health (earlier 
Veterinary and Food) of the ministry.
The current measures are as follows: if a bovine animal is suspected of having EBL 
based on clinical symptoms (e.g. tumorous external lymph nodes) or pathological 
or meat inspection fi ndings (e.g. lymphoid tumors in several organs), histological 
and serological samples must be taken and examined in the National Veterinary 
and Food Research Institute. The herd of origin (as a suspected leukotic herd) is 
placed under restrictive measures by the offi cial municipal veterinarian. Restric-
tions can also be imposed on a herd on the basis of the annual bulk-tank milk sur-
veillance results. Serum samples from all bovine animals of the herd are examined 
for antibodies against BLV immediately and again after three months at the ear-
liest. All bovine animals over two years old are also examined clinically. If all re-
sults turn out negative the restrictions are withdrawn. If seropositive animals are 
found, the restrictions are maintained until all such animals are slaughtered and 
the other animals are found to be seronegative in samples taken no sooner than 
three months after the last slaughter. Pending application by the owner and the 
recommendation of the district veterinarian, the authorities can order the slaugh-
ter of seropositive animals at the partial expense of the state. The clinical exami-
nation of animals suspected of leukosis and the taking of appropriate samples by 
the veterinarian, pursuant to the Circular, are also recompensed by the state. The 
restrictions are only withdrawn when all animals are seronegative. The municipal 
and district veterinarians are obliged to conduct a further epidemiological investi-
gation to map the spread of the infection. If sheep are also kept on the farm the 
district veterinarian decides on the testing of these animals.
The Veterinary Department letter 1104 / 143 (1981) concerning health moni toring 
programme for AI bulls stipulated that an AI bull had to be tested for anti bodies 
against BLV before entering the AI station, and before sending it from the sta-
tion to slaughter. The MAF circular 3 / 93, replacing 1104 / 143 and laying down the 
health requirements for bovine semen, necessitated that bull calves to be sold to 
rearing stations and their herds of origin must be tested for antibodies against BLV. 
The calves had to be retested at the rearing station and as bulls at the AI station at 
least once a year for BLV antibodies, with negative results. If a bull seroconverted 
while in the station the semen taken since the last seronegative result could not 
be used. The MAF decree 6 / EEO / 2004 replaced circular 3 / 93, but the requirements 
have been preserved. The circular 1 / 94 of MAF, laying down the health require-
ments for bovine embryos, requires that the herd of origin of the donor animal 
must have been free of EBL for the previous 3 years, or otherwise shown to be free 
of the disease.
EU legislation Annex E (I) to Directive 64 / 432 / EEC, last amended in 1997 (Directive 
97 / 12 / EC), lists EBL among the compulsorily notifi able bovine diseases. Annex D to 
Directive 64 / 432 / EEC, last amended in 1998 (Directive 98 / 46 / EC), defi nes the crite-
ria for offi cially EBL-free herds, Member states and Regions. Community measures 
for the eradication of leukosis in cattle were introduced in Directive 77 / 391 / EEC, 
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and the minimum criteria that the national plans for the eradication of EBL should 
satisfy to receive a fi nancial contribution from the Community were established 
in Directive 78 / 52 / EEC. Mainland Finland has since 1996 been offi cially free of EBL 
(latest Decision 2004 / 320 / EC, Annex V).
Decision 98 / 372 / EC concerning the animal health conditions for imports of live bo-
vine animals from certain European countries requires that the herds of origin of 
the animals to be imported must be EBL-free as defi ned by Annex 5 to the Decision 
and tested for antibodies against BLV within a month before import, with nega-
tive results. Animals intended for meat production or to be transported directly to 
slaughter must come from herds included in national programmes for the eradi-
cation of EBL. Directive 2003 / 43 / EEC, the fi fth amendment to Directive 88 / 407 / EC 
laying down the animal health requirements applicable to intra-Community trade 
and imports of semen of bovine animals, requires that the donor bulls to be quar-
antined before entry to the AI station must come from an offi cially EBL-free herd, 
or produced by dams tested for antibodies against BLV with negative results. The 
bulls must be tested within 28 days preceding the quarantine, and at least once a 
year in the AI centre for antibodies against BLV with negative results. If the test re-
sult of a bull while in the AI station is positive the animal must be isolated and the 
semen collected since the last negative test may not be subject to intra-commu-
nity trade. Decisions 94 / 113 / EC and 2005 / 217 / EC, amending Directive 89 / 556 / EEC 
on animal health conditions governing intra-Community trade in and importation 
from third countries of bovine embryos, requires that the donor animal must come 
from a herd that is EBL-free, or from a herd that is not EBL-free but for which cer-
tifi cation has been obtained that there have been no clinical cases of EBL during 
the previous three years. 
MV
Domestic legislation Maedi–visna in sheep and caprine arthritis encephalitis (CAE) 
in goats are notifi able animal diseases according to the MAF decision 1346 / 1995, 
and cases of MV and CAE must be reported without delay to the Department of 
Food and Health (earlier Veterinary and Food) of the ministry. The current decree 
on the control of MV and CAE was given in 2001 (MAF 15 / EEO / 2001). This decree 
replaced MAF decision 1 / EEO / 1999 on the subject. 
The current measures are as follows: if there are reasonable grounds to suspect 
that sheep of a fl ock have MV the municipal veterinarian places offi cial restric-
tive measures on the fl ock and takes samples to confi rm the diagnosis. The restric-
tive measures prohibit the movement of the animals to or from the farm except 
to slaughter, and delivery of sheep-based products to other sheep or goat farms 
requires permission from the district veterinarian. If the diagnosis is confi rmed, 
blood samples are taken from all sheep over 1 year of age and tested for anti-
bodies against MVV. The district veterinarian is obliged to conduct an epidemio-
logical investigation to trace the source of the infection and those contact herds 
where the infection may have spread further. The offi cial restrictive measures are 
also imposed on all suspected contact herds and all sheep over 1 year of age in 
each are tested for antibodies against MVV. Costs from sampling and laboratory 
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examinations are defrayed by the state. The restrictive measures are withdrawn 
only if the diagnosis is not confi rmed in the laboratory examination of the samples, 
if all infected (seropositive) animals and their progeny are culled and the other 
sheep over 1 year of age test negative for antibodies against MVV in two subse-
quent samplings, 5–7 months and 12–16 months after the fi rst sampling, or if at 
least 14 days have passed after the slaughter of all sheep and goats and disinfec-
tion of the premises.
EU legislation Directive 91 / 68 / EEC defi ning the animal health conditions govern-
ing intra-Community trade in ovine and caprine animals requires that animals for 
breeding must have been obtained from a holding and must only have been in 
contact with animals from such a holding in which MV has not been clinically di-
agnosed in the previous three years. This period shall be reduced to 12 months 
in the animals infected with MV have been slaughtered and the remaining ani-
mals react negatively in two subsequent tests for antibodies against MVV. Health 
guarantees provided for the herds by approved control programmes also meet the 
requirements for trade. Directive 91 / 68 / EEC lists MV in Annex B III as one of the 
diseases for which national control programmes can receive fi nancial contribution 
from the Community, according to Decision 90 / 424 / EC. Directive 92 / 65 / EEC, laying 
down animal health requirements governing the trade in and imports into the 
Community of, for instance, semen of sheep, requires that the animals used for the 
collection of semen fulfi l the criteria laid down in Directive 91 / 68 / EEC for animals 
intended for breeding. 
4.1.2 Control programmes
BVD
A voluntary BVD control program was launched by the Veterinary and Food De-
partment of MAF in 1994. The programme included both dairy and beef herds, and 
was based on formal affi liation to the programme and meticulous recording of 
animal-related events in the herd by the owner. The herds were tested twice with 
4–12 month intervals either using BTM or individual sera as samples, and classifi ed 
either as BVD-free I or II class herds, or BVD herds. Herds in BVD-free class I had nei-
ther antibodies against BVDV nor showed any indication of infection. Animals in 
herds classifi ed as BVD-free class II had antibodies against BVDV but there was no 
indication of active infection in the herd. BVD herds contained animals positive in 
the virus isolation test (PI animals). The programme contained detailed instructions 
concerning the regular serological follow-up of the herds, the trade of animals be-
tween herds, visits of animals to exhibitions and measures to eradicate the active 
infection from BVD herds.
The voluntary control programme launched in 1994 expired at the end of 2004. The 
new decree (MAF 2 / EEO / 2004) provided a reviewed voluntary BVD health control 
scheme for cattle herds. The control scheme is recommended especially for farms 
that actively sell animals for breeding, or that have joined an embryo-ring opera-
tion. The new scheme, like the old control programme, is based on regular testing 
of the herds for antibodies against BVDV, and the commitment of the herd owners 
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to comply with the requirements of the scheme; however, the classifi cation of herds 
has been removed. The new scheme sets new time limits for the regular retesting 
of the herds. After the fi rst two tests for antibodies against BVDV with a 7 to 18-
month interval the herd has to be retested with an interval of at most 24 months. 
The annual BTM surveillance testing is accepted for the purposes of the scheme. 
The scheme is also more explicit with regard to embryo transfer and artifi cial in-
semination than the old control programme. The semen used in a herd that has 
joined the control scheme must come from an offi cially approved AI centre, and the 
embryos from the same herd or from another herd in the scheme. If this is not the 
case the dam that has conceived must be examined for antibodies against BVDV at 
the earliest 4 weeks but at most 12 weeks after the insemination or embryo trans-
fer. If the dam seroconverts it must be isolated before parturition. The offspring 
must also be isolated and examined for BVDV as soon as possible. The stipulations 
for trade and contact with other herds such as visits to exhibitions have mainly 
been preserved from the old programme. The municipal veterinarian is obliged 
to issue a health certifi cate to herds both in the scheme and not in the scheme 
provided that the conditions of the voluntary scheme have been observed.
In addition to the offi cial control programme, a voluntary control or “sanitation” 
programme for dairy herds found to have antibodies against BVDV in BTM was 
set up by the VALIO dairies cooperative in 1994. The sanitation agreement be-
tween the farmer and the associated dairy required that all the bovine animals 
> 3 months of age in the herd were tested to identify the seronegative PI-animals. 
If found they were slaughtered and about a year later 3 to 15-month-old animals 
were tested. The latter included those that were too young to be tested in the fi rst 
round. The costs of sampling and laboratory examinations were defrayed by the 
associated dairy; however, the owner took care of the expenses due to slaughter-
ing the PI animals. The farmer further agreed to obtain new animals for the herd 
only from known BVD-negative herds. The Association for Animal Disease Preven-
tion (ETT ry) took over the administration of the sanitation programme in 2000. 
The programme was eventually replaced by the decree MAF 2 / EEO / 2004.
IBR
The MAF circular 1 / 93 laying down the control measures for IBR does not include 
further control programmes or schemes.
EBL
The MAF circular 2 / 93 laying down the control measures for EBL contained a pro-
gramme that set standards by which a herd could be declared and remain free of 
EBL. The programme was voluntary except for herds selling bulls to AI stations or 
exporting live animals into the European Community. A cattle owner could join 
the programme through written agreement with the municipal veterinarian. Ad-
hering to the programme required detailed accounting of the animals’ identifi ca-
tion, dates of birth, slaughtering or cause of death, selling to or buying from other 
herds, and copies of health certifi cates. 
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Achieving the EBL-free status required that:
– All bovine animals > 24 months old and those < 24 months old and introduced 
to the herd from herds of unknown EBL-status were tested twice at 4–12 month 
intervals for antibodies against BLV. A BTM sample in dairy herds could be used 
for testing, but the animals not contributing to BTM (dry cows, those treated 
e.g. with antibiotics, heifers and bulls) must have been sampled individually.
– All the results were negative and no clinical signs of EBL or BLV infection had 
been detected for the previous two years.
– If an animal was introduced from a herd of unknown EBL status it must have 
been tested for antibodies against BLV within 30 days prior to the intended 
transfer with negative results. The transferred animal must have been kept in 
isolation for at least 4 months and then retested for BLV infection. If the in-
troduction took place between the fi rst two tests of the entire herd, then the 
second testing could be done at the earliest 4 months after the introduction of 
new animals.
– If a new herd was composed entirely of animals from certifi ed EBL-free herds, 
the district veterinarian could approve its EBL-free status on this basis. How-
ever, the herd must have been tested for antibodies against BLV 4–6 months 
after the approval, with negative results.
The municipal veterinarian was obliged to issue a health certifi cate to a herd ful-
fi lling the criteria above.
Maintaining the EBL-free status required that:
– All the animals > 24 months old in an EBL-free herd must have been tested for 
antibodies against BLV every third year. As above, a BTM sample in dairy herds 
could be used for testing but animals not contributing to the BTM must have 
been sampled individually.
– New animals introduced to an EBL-free herd must without additional testing 
have come from a certifi ed EBL-free herd. If an animal came from a herd of un-
known EBL status it must have been > 24 months old and tested for BLV infec-
tion within 30 days prior to the intended transfer, with negative results. The 
transferred animal must have been kept in isolation for at least 4 months and 
retested. The transfer of animals < 24 months old needed permission from the 
district veterin arian.
The programme contained further stipulations and conditions for visits to ani-
mal exhibitions and other happenings, for contact with animals of other herds 
on pasture, and AI and embryo transfer activities. However, this programme for 
herd-level EBL-freedom (part 8) of the circular was removed in 1997 (MAF decision 
15 / EEO / 97) when mainland Finland was declared offi cially free of EBL.
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MV
The fi rst control programme for MV, approved by the MAF, was launched in 1995. 
This programme was voluntary. The current decree on the control of MV (MAF 
15 / EEO / 2001) also contains a health control programme (part 9) which is compul-
sory for fl ocks with more than 20 ewes. The new programme is only slightly re-
vised from the previous voluntary programme. The MV control programme takes 
into account the slowly progressing nature of the disease necessitating constant 
clinical and serological moni toring of the health status of the fl ocks. Joining the 
programme, having the scheduled serological tests done on the fl ock and observ-
ing the other conditions of the programme enable the sheep farmer to obtain a 
stepwise rising health status and eventually the offi cial MV-free status for his fl ock. 
All the sheep in the fl ock must be listed and accounted for, and animals that are 
tested for MV must have some form of individual identifi cation, e.g. an ear tag. 
The list of animals > 12 months of age must contain the following information: 
breed, gender, identifi cation number, date of birth, pedigree, date of slaughter or 
date and cause of death. Detailed data on all purchases, selling or movements of 
animals, and contact information on the buyers or sellers must also be available. 
The programme furthermore contains detailed instructions for acquiring new ani-
mals from other herds and contact with other herds, e.g. through animal exhibi-
tions. Costs from examination of all of the samples as well as those incurred from 
compulsory sampling are defrayed by the state; however, the owner has to cover 
those incurred from voluntary sampling. The control programme is schematically 
presented in Figure 1. 
4.2 Development in the disease situation
4.2.1 General
Prior to 1990 the moni toring of domestic animals for viral diseases mainly consisted 
of annual statistics compiled from the results of samples sent in to the central vet er-
in ary laboratory because of mandatory testing of specifi c animals or animal groups, 
to be examined for a particular viral infection or disease, or to determine the cause 
of death of an animal. The latter frequently also included virological exam in ations. 
While these statistics do in a very general way refl ect the viral disease situation, no 
actual prevalence studies with proper random sampling were conducted. Screen-
ing of bulk-tank milk samples of dairy herds for antibodies against selected viral 
disease agents, introduced in 1990, began to signifi cantly improve knowledge of 
the actual occurrence of the bovine infections or diseases BVD, IBR and EBL. A rea-
sonably comprehensive annual serological survey for antibodies against the MV 
virus among sheep breeding fl ocks, started in 1994, gave corresponding cross-sec-
tional information on the occurrence of MV in Finland.
4.2.2 Materials and methods
The results of the virus neutralization tests, haematological, serological and bulk-
tank milk surveillance examinations (I–V) were extracted from annual statistics 
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compiled by the Finnish National Veterinary Institute (since 1994 the National Vet-
erinary and Food Research Institute EELA). Offi cial meat inspection data (IV) were 
compiled from the annual statistics of the Veterinary Department of MAF. Detailed 
information of applied control and eradication measures were obtained from the 
archives of the State Provincial Offi ce of Southern Finland (III). The insemination 
Figure1 MV control programme for sheep. Reprinted from V, p 216, with permission from 
Elsevier.
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statistics of the herds (III) were obtained from the registers of ProAgria Agricultural 
Data Processing Centre Ltd, Vantaa Finland, with permission from the herd own-
ers. The individual groups of animals from which the haematological or serological 
samples were taken, are identifi ed in the descriptions of the developments in the 
disease situation below.
The haematological method (IV) consisted of counting the leukocytes of a blood 
sample in a counting chamber and applying the classifi cation key of Bendixen 
(1965) to the results. The serological methods consisted of in-house virus neutrali-
zation tests (BVD prior to 1990, III) and in-house (IV) or commercial agar gel im-
munodiffusion (AGID) assays (V). Commercial enzyme immunoassays (EIA or ELISA) 
were used to examine the serum and bulk-tank milk samples since 1990 (I–IV). 
Micro plate readers were used to measure the optical densities of the kit test plate 
wells and associated software to process and interpret the raw data. The presence 
of BVD virus in serum samples was determined by culturing in bovine turbinate 
cells (I) or using the immunoperoxidase method (II). Details of the tests and Infor-
mation of the vendors of the commercial kits can be found in the original publi-
cations. 
4.2.3 Situation according to health moni toring
BVD (I, II)
Rislakki (1961) mentioned that antibodies against viral diarrhoea virus had also 
been tested for in samples taken to study the occurrence of para-infl uenza in cat-
tle, but had not been found. However, Estola (1964) noted this disease in his review 
on animal virus diseases in Finland, and claimed a low level of occurrence. Positive 
fi ndings from serological testing for antibodies against BVDV were occasionally 
reported in the annual statistics of the National Veterinary Institute (Table 7). The 
samples came from individual animals and information on the numbers of herds 
they represented is no longer available. However, the small numbers of samples 
examined in most years before 1987 indicate that the number of herds must have 
been only a small fraction of the total.
IBR (III) 
Moni toring for IBR among specifi c groups of animals started in 1965 (Table 7). The 
tested animals consisted mainly of heifers to be exported, live animals imported to 
Finland, and animals with a respiratory infection for which a defi nite diagnosis was 
considered necessary. Compared to the numbers of samples examined for BVD the 
annual numbers for IBR show a moderate increase. The average number of sam-
ples examined was 68 in 1965–1973 (range 4–159), 661 in 1974–1985 (range 335–
890), and 2126 in 1986–1989 (range 523–2947). The samples came from individual 
animals and information on the numbers of herds they represented is no longer 
available. Even between 1986 and 1989 the average number of samples repre-
sented only some 0.15% of the contemporary cattle population and the fraction of 
herds they came from was most likely of the same order of magnitude.
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Table 7 Annual animal health monitoring data, 1965–2004
 Diseases 
Year BVD IBR EBL MV 
1965 3 / 101 0 / 8 –2 – 
1966 0 / 10 0 / 20 222 / 5 094 – 
1967 0 / 2 0 / 4 314 / 10 823 – 
1968 33 / 92 0 / 92 169 / 8 140 – 
1969 0 / 94 0 / 107 127 / 6 789 – 
1970 0 / 25 1 / 87 43 / 6 174 – 
1971 2 / 11 13 / 89 60 / 6 773 – 
1972 7 / 22 0 / 75 87 / 6 962 – 
1973 0 / 13 0 / 159 49 / 6 180 – 
1974 0 / 76 0 / 441 34 / 5 477 – 
1975 0 / 23 0 / 506 35 / 6 230 – 
1976 0 / 40 0 / 782 28 / 5 543 0 / 144 
1977 0 / 12 0 / 355 15 / 5 548 0 / 23 
1978 0 / 34 0 / 654 14 / 3 720 0 / 8 
1979 5 / 93 0 / 748 90 / 11 5433 0 / 10 
1980 0 / 62 0 / 694 48 / 9 020 0 / 3 
1981 0 / 44 0 / 718 76 / 10 062 3 / 102 
1982 1 / 12 0 / 660 68 / 10 694 – 
1983 10 / 66 0 / 776 58 / 9 642 – 
1984 0 / 307 0 / 890 28 / 8 795 – 
1985 0 / 40 0 / 734 27 / 9 951 0 / 140 
1986 0 / 161 0 / 2 947 12 / 9 052 0 / 108 
1987 0 / 1176 0 / 2 872 11 / 9 049 0 / 2 
1988 24 / 1 699 0 / 2 352 14 / 7 163 0 / 7 
1989 7 / 509 0 / 1 014 7 / 8 237 0 / 207 
1990 199 / 521 3 / 2 920 18 / 7 839 0 / 291 
1991 208 / 4 698 97 / 6 624 28 / 7 373 0 / 120 
1992 221 / 6 135 1 / 7 496 26 / 8 490 – 
1993 141 / 5 465 0 / 4 954 24 / 7 139 – 
1994 2 832 / 16 524 0 / 5 237 7 / 9 604 46 / 12 931 
1995 936 / 9 480 0 / 3 078 13 / 7 326 12 / 10 362 
1996 196 / 4 100 0 / 2 343 4 / 6 139 8 / 14 118 
1997 303 / 2 841 0 / 2 903 2 / 4 723 0 / 14 095 
1998 330/ 2 323 0 / 2 125 0 / 4 616 0 / 10 802 
1999 494 / 2 565 0 / 2 298 0 / 3 278 0 / 10 312 
2000 447 / 3 913 0 / 2 688 0 / 2 781 0 / 6 769 
2001 491 / 3 620 0 / 2 132 0 / 2 095 1 / 12 427 
2002 98 / 2 898 0 / 2 020 0 / 2 230 1 / 16 783 
2003 22 / 3 150 0 / 2 313 0 / 2 296 0 / 16 602 
2004 312 / 3 588 0 / 1 790 0 / 1 977 0 / 16 356 
1 no. positive / no. tested 
2 no record available 
3 before 1979 hematological and since then serological results
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The infection was encountered for the fi rst time in December 1970, when the se-
rum of an AI bull showing signs of respiratory infection tested positive for antibod-
ies against BHV-1. On closer (and partly confi rmatory) testing in 1971, nine of its 
station mates were also found to have antibodies against the virus. Between 1972 
and 1989 the antibodies were not encountered in health moni toring (Table 7), but 
in 1990 calves with signs of respiratory infection in a large herd turned out to be 
seropositive against BHV-1. This herd was also positive in the fi rst BTM surveillance 
in the same year. The total number of herds with BHV-1 infection in the subse-
quent investigation and BTM surveillance in 1991 was fi ve and the total number of 
seropositive animals in these herds was 90. Health moni toring from 1992 onwards 
has not revealed any new seropositive herds. Strict control measures in 1991 elimi-
nated the infection from all but one herd. The last BHV-1 infected herd was en-
tirely stamped out in 1994.
EBL (IV)
Berger and Henriksson (1966) were the fi rst to note the presence of EBL in Fin-
land and the need for control measures against it. Compared to BVD and IBR the 
health moni toring for BLV infection or manifest EBL has been more intense since 
that year. Information on the occurrence of the infection or disease was based on 
meat inspection statistics and haematological testing between 1966 and 1978 and 
subsequent serological moni toring since 1979 (Table 7). The haematologically posi-
tive PL animals were those classifi ed into Bendixen group III (Bendixen, 1961). The 
haematologically or serologically tested samples were drawn from three groups of 
animals: i) herds suspected of leukosis on clinical or meat inspection grounds, herds 
of origin of bull calves intended for AI service and herds sold at auction (on aver-
age 80–85% of the samples); ii) heifers exported to the Soviet Union (15–20%); and 
iii) occasionally the AI bulls (1–2%). The average number of leukotic animals found 
in meat inspection / 100 000 animals at slaughter between 1968 and 1978 was 11 
(range 3–19). The average proportion of positive haematological results between 
1966 and 1978 was 1.4%. A decreasing trend was apparent in the proportions of 
positive serological results from 0.8% in 1979 to 0.04% in 1997. In addition to con-
fi rmatory testing for meat inspection fi ndings, the samples came from individual 
animals and information on the numbers of herds they represented is no longer 
available. The moni toring results have been negative since 1997.
MV (V)
The fi rst record of samples being tested for antibodies against MVV is from 1976, 
according to the annual statistics of the National Veterinary Institute (Table 7). 
A small number of samples were tested annually in 1976–1981, and then again 
in 1985–1991. The testing was associated mainly with the conditions of import 
and specifi c diagnostic purposes. The fi rst positive results in the health moni toring 
came from samples of three imported sheep in 1981. Since the (re)detection of MV 
infection in Finland in 1994 the health moni toring of sheep for MV has been con-
siderably increased (Table 7).
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4.2.4 Situation based on annual BTM surveillance data (I–IV)
The fi rst BTM surveillance for antibodies against specifi c viruses took place in 1990. 
In that year the random sample of dairy herds examined covered about one-fourth 
of all dairy herds. Since 1992 a laboratory sample of BTM has been obtained from 
virtually every dairy herd in the country. The laboratory samples have been exam-
ined for IBR and EBL since 1990. In 1992 a random sample of 5 024 of the 37 923 
laboratory BTM samples collected in the same year were tested for BVD. Since 1993 
all of the BTM laboratory samples have also been tested for BVD. The numbers of 
laboratory samples examined and the results as herd level seroprevalence for BVD, 
and numbers of IBR and EBL positive BTM samples between 1990 and 2004 are pre-
sented in Table 8. The numbers are compiled from the annual animal disease sta-
tistics of the National Veterinary and Food Research Institute, EELA (previously Na-
tional Veterinary Institute).
Table 8 Annual dairy herd BTM surveillance data, 1990–2004
  Diseases 
 BTM BVD IBR EBL
Year no. tested % positive no. positive no. positive 
1990 9 879 –1 3  4 
1991 36 889 – 1  8 
1992 5 024 / 37 9232 0.80 1 11 
1993 34 115 0.96 1  4 
1994 34 169 0.99 1  3 
1995 32 588 0.66 0  1 
1996 30 569 0.37 0  1 
1997 28 577 0.42 0  0 
1998 26 934 0.37 0  0 
1999 24 872 0.36 0  0 
2000 22 698 0.45 0  0 
2001 21 040 0.24 0  0 
2002 19 870 0.29 0  0 
2003 18 519 0.15 0  0 
2004 17 300 0.23 0  0 
1 not tested
2 no. tested for BVD / no. tested for IBR and EBL
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4.2.5 Situation based on annual beef and suckler-cow herd 
 surveillance data, 1993–2004 (I–IV)
Individual serum samples of beef and suckler-cow herds were obtained on farm 
premises in 1993–1994, and at slaughter since 1995. From 2003 the sampling has 
been targeted especially at suckler-cow herds using the type of production data in 
the central bovine register (Rikula and Joutsenlahti, 2004). The numbers of samples 
examined and the numbers of positive results for BVD, IBR and EBL are presented 
in Table 9. The results are shown as absolute numbers to avoid the impression that 
they are actual prevalences. However, the targeted sampling in 2003–2004 has cov-
ered > 90% of the approximately 1300 suckler-cow herds so that an estimate for 
herd-level prevalence is reasonably accurate. This estimate is 0.4% for 2003 and 
0.15% for 2004. 
4.2.6 Development in the BVD PI-herd and MV-positive sheep 
flock situation (I, II, V)
Further information on the occurrence of the infections or diseases BVD, which 
can be considered endemic, and MV, which can still claim a sporadic occurrence 
in Finland, is presented in Table 10. Except for the fi rst three years, 1994 to 1996, 
the annual numbers of cattle herds with PI animals show no clear trend. Compari-
Table 9 Annual beef cattle and suckler-cow herd surveillance data, 1993–2004
  Diseases 
 No. samples BVD IBR EBL
Year tested no. positive no. positive no. positive
1993 3 248 54 0 0
1994 12 764 64 0 0
1995 2 544 40 0 0
1996 2 839 24 0 0
1997 2 845 18 0 0
1998 2 758 21 0 0
1999 2 920 24 0 0
2000 2 899 17 0 0
2001 2 996 10 0 0
2002 2 816  9 0 0
2003 6 7531  2 0 0
2004 4 248  7 0 0
1 sampling targeted to suckler-cow herds in 2003–2004
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son of the data in Tables 8 and 10 indicates that the annual incidence risk of PI 
herds in Finland agrees well with the range of 0.02–0.03 cited by Lindberg (2002). 
The numbers of sheep fl ocks tested for MV between 1994 and 2004 represented 
roughly one-third of sheep farms according to the main production sector data 
(TIKE, 2005); it was 29.1% in 2001 and 37.0% in 2002. The main production sector 
sheep farms form approximately a half of all of the sheep farms receiving agricul-
tural subsidies according to the IACS register data (TIKE, 2005).
Table 10 Number of BVD PI herds and MV status of sheep fl ocks, 1994–2004
 Cattle Sheep fl ocks 
 no. of BVD no. tested no.
Year PI herds for MV positive 
1994 27 545 8 
1995 13 431 4 
1996  1 507 1 
1997  1 430 0 
1998  6 340 0 
1999  4 297 0 
2000  7 185 0 
2001  9 265 1 
2002  2 320 1 
2003  0 307 0 
2004  2 275 0 
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5 Discussion
5.1 Assessment of the measures applied in Finland
5.1.1 General approach in assessment
An overall appreciation of the effi ciency of the control and eradication measures 
can be gained by the actual results, i.e. development of the infection or disease sit-
uation. The combined effi cacy of the measures could in theory be tested quantita-
tively for each affl iction by comparing the observed developments to a hypotheti-
cal situation of “no control measures applied”, with some appropriate statistical 
procedure. However, this zero-control situation is not available, and the approach 
needs to be an essentially qualitative assessment based on compiling the existing 
information.
A central factor in determining the disease situation is the performance of the ap-
plied diagnostic tests. The diagnostic sensitivity and specifi city are essentially pop-
ulation parameters that describe the test performance for a given reference popu-
lation (with a given distribution of covariance factors), under defi ned conditions 
(laboratory, chosen cut-off, etc). The available information of the sensitivities and 
specifi cities of the employed tests is given in the original publications and sum-
marized above for each disease in the diagnostic test performance subsections. 
However, in practice the lack of proper gold-standards usually prevented a critical 
evaluation of the alleged performance in the actual target population and given 
in-house conditions. Having to resort to intra-test controls only was tolerated be-
cause it was considered that this less than optimal situation was offset by the fact 
that each herd and in some instances each animal was tested repeatedly.
To establish at least some transparency and structure in the assessments of the ap-
plied control measures the reproduction ratio of infections, denoted with R, some-
times (curiously) referred to as reproductive rate (e.g. Lindberg, 2002) will be em-
ployed. This term is a dimensionless multiplication factor that refers to the average 
number of secondary cases generated by one primary case during its infectious 
period (Anderson and May, 1982). A specifi c case of R is the basic reproduction 
ratio, R 0 , which refers to the situation when one infective individual is introduced 
into a population consisting entirely of susceptible individuals. Although the nota-
tion R 0 strictly speaking relates only to the theoretical specifi c case, it appears cus-
tomary in the literature to use this symbol to also mean the net or effective R (e.g. 
Hallo ran, 1998). R 0 is considered useful in evaluating different strategies or inter-
ventions for disease control (Graat and Frankena, 1997; Halloran, 1998; Lindberg 
and Houe, 2005). R 0 for a specifi c type of contact can be conceptualized as a com-
posite of three components: the probability of transmission for the contact type 
(β), the frequency of these contacts per time unit (c), and the duration of the infec-
tious period (D), or as a formula:
             R 0 = β × c × D
Some notes or specifi cations of the components need to be made. Halloran (1998) 
reported that the transmission probability (β) depends on characteristics of the in-
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fectious host, of the susceptible host, of the parasite and on the defi nition of the 
contact. The characteristics of the infectious and susceptible host are reduced in the 
formula into some average or typical values, which of course is a gross over-sim plifi -
cation. The general health or immune status of the susceptible host, for example, 
can have a substantial effect on the transmission probability. Characteristics of the 
parasite, translated into inherent transmissibility of the etiological agent (Fraser 
et al., 2004), are also an important strain-dependent variable, although not amen-
able to control. There are also further assumptions including a constant frequency 
of infectious contacts and uniform infectivity during the infectious period. 
To be useful in assessing intervention measures the three components should be 
independent of each other, or at least clearly separable. However, the frequency 
of infectious contacts (c) depends on the presence of the infectious animal(s), i.e. 
on the length of the infectious period (D). Once or if the infectious animal is, for 
instance, culled from the herd the frequency obviously drops to zero. If some inter-
vention in the assessments below aims in the fi rst place to shorten D then the sec-
ondary effect on c will not be considered. The length of the infectious period, D, 
does have an upper limit, i.e. the length of the period in the course of natural in-
fection. Shortening of this period is one of the important intervention measures 
available, especially with agents of infections that are able to establish a persist-
ent infection. For the sake of clarity, this component could also be denoted with 
D int in the formula.
Thurmond (2005) suggests a fourth component to the equation, namely the re-
duction in the number of susceptible individuals in the population, as per vaccina-
tion, but does not present an explicit way to add the component to the formula. 
The effect of this factor could be included either in component β (characteristics 
of the susceptible host, Halloran, 1998), or component c in the formula. Nokes and 
Anderson (1988) simply replace the frequency c with the number of susceptibles 
present. Graat and Frankena (1997) present a formula for “number of effective 
contacts”, or R 0 , where component c is replaced with terms of classical compart-
mental SIR model, in the form S t × I t × N (S t for proportion of susceptible and I t for 
proportion of infectious animals at time t, and N for total host population). Reduc-
ing the absolute number or proportion of the susceptibles leads directly to a de-
crease in R 0 . Anderson and May (1991) allow for the susceptibles with the relation 
R = R 0 × x, where x is the proportion of susceptible animals in the population. 
The heuristic simple formula above is, as defi ned, valid only for one specifi ed type 
of contact producing a single type of infection, or “single infected compartment” 
(van den Driessche and Watmough, 2002). A more general or realistic formula ac-
counting for all major types or compartments would need a substantially more 
rigorous approach (Farrington et al., 2001). The assessments of the disease con-
trol measures (below, in Tables 11–14) inevitably group together more than one 
specifi able type of infectious contact or compartment. The levels of infl uence of 
the measures on the three components are assigned in keeping with what is un-
derstood to be the strongest and not some hardly determinable average infl uence. 
Nevertheless, given the simplifi cations and groupings the plain deterministic for-
mula is considered suffi cient for the present rudimentary assessment of the con-
trol measures.
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A numerical value for R 0 is by defi nition the initial upper boundary value for the 
net reproduction ratio R. The simple equation can only yield very sketchy numeri-
cal estimates for R (Thurmond, 2005). Models for more accurate estimating of R 0 
may be classifi ed roughly into three groups depending on the data required (Far-
rington et al., 2001). The fi rst is to build up a mathematical expression for it using 
parameters describing the contact structure in the target population, while the 
second approach relies on the time series data of susceptibles and cases, or fi nal 
epidemic size data in a defi ned population. The third approach is to derive expres-
sions for R 0 based on quantities estimated from the endemic equilibrium of the 
infection, such as aggregated surveillance data or serological surveys. However, 
a numerical value obtained in one setting can only be generalized with consider-
able provisos. The overall R 0 can be refi ned to within-herd (between individual) 
and between-herd R 0 , which most likely have different values for a given infec-
tion. Available numerical estimates or reasonable deductions for the reproduction 
ratios of the infections are presented below. The R 0 is frequently considered to be 
a threshold parameter: for R 0 < 1 the epidemic will eventually die out, while for R 0 
> 1 the infection will spread. Implicit in the formulas for R is that the host popula-
tion should be reasonably large in number to reach a meaningful stability in the 
parameters, for example in the frequency of infectious contacts. This does not nec-
essarily materialize in small herds and chance fl uctuations may be the deciding fac-
tor in the course of an outbreak within such a herd. 
5.1.2 Assessment of the measures in terms of reproduction ratio R
The assessments are in each case based on intrinsic determinants of the hosts 
(Table 1), host–agent relationships (Table 2), and especially on sources of the agent 
and means of transmission (Table 3).
BVD
The measures to control BVD, the components of both within-herd and between-
herd R they infl uence and their assessed thrusts are compiled in Table 11. 
Numerical estimates for the basic reproduction ratio of BVD infection have been 
presented by Cherry et al. (1998). The within-herd R 0 was estimated at 2.3 without, 
but at 35.0 with PI animals in the herd. Lindberg and Houe (2005) present semi-
quantitative estimates for the transmission probability and frequency of infectious 
contacts for transmission of BVDV between herds, but do not venture to combine 
the estimates to derive actual numerical reproduction ratios.
IBR
The measures to control IBR, the components of both within-herd and between-
herd R they infl uence and their assessed thrusts are compiled in Table 12.
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Table 11 Assessment of BVD control measures using the disease reproduction ratio
  Infl uence on Within Between
Measure component herd1 herds1
Annual health monitoring and   βa 0 0
surveillance data cb 0 1
  Dc 1 2
Voluntary programs 1994–2004, 2005–  
 Culling of PI animals β 0 0
  c 0 0
  D  1 2
 Biosecurity measures β 1 2
 (conditions on trade c 1 2
 and other contacts, etc) D  0 1
 Conditions on AI and β 1 1
 embryo transfer (2005–) c 2 2
  D  0 0
Measures of the decree 2 / EEO / 2004  
 Restrictive measures on farm  
  Culling of PI animals β 0 0
  and their progeny < 3 months of age c 0 0
  D  2 2
  Restrictions on animal movements β 0 2
  c 0 2
  D  0 0
  Biosecurity measures (mandatory β 1 2
  reporting to stakeholders, c 1 2
  protective clothing for visitors, etc) D  0 0
 Epidemiological investigation β 0 2
 (tracing of contact herds) c 1 2
  D  0 2
Measures of the decree 6 / EEO / 2004 of MAF β 0 1
and Directive 2003 / 43 / EEC (animal health c 2 2
requirements in respect to bovine semen) D  0 0
1 scale: 2, major; 1, minor; 0, negligible
a probability of transmission in a given contact type  
b frequency of infectious contacts of the given type  
c duration of the infectious period
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Table 12 Assessment of IBR control measures using the disease reproduction ratio
  Infl uence on Within Between
Measure component herd1 herds1
Annual BTM surveillance and βa 0 0
health monitoring data cb 1 2
  Dc 1 2
Classifi cation according to decision 426 / 93  β 0 0
of MAF (immediate notifi cation of authorities) c 1 2
  D  1 2
Measures of the circular 1 / 93 of MAF  
 Restrictive measures on farm  
  Isolation of seropositive and β 0 0
  clinically ill animals c 0 0
  D  2 1
  Restrictions on animal movements β 0 0
  c 0 0
  D  0 2
  Restrictions on delivery of semen β 2 2
  and use of animals for natural mating c 2 2
  D  0 0
  Biosecurity measures β 1 2
  (avoidance of unnecessary visits to c 1 2
  animal shed, use of protective clothing) D  0 0
 Culling of seropositive animals β 0 0
 and serological follow-up of entire herd c 0 0
  D  2 2
 Epidemiological investigation β 0 0
  (tracing of contact herds) c 1 2
  D  0 2
Measures of the decree 16 / EEO / 1997 of MAF β 0 0
(Health control program for deer farms) c 0 1
  D  0 0
Measures of the decree 6 / EEO / 2004 of MAF β 0 2
and Directive 2003 / 43 / EEC (Animal health c 0 2
requirements in respect to bovine semen) D  0 0
Measures of the Decisions 94 / 113 / EC  β 0 1
and 2005 / 217 / EC (trade and import  c 0 1
of bovine embryos) D  0 0
Additional guarantees of the Community  β 0 0
(Decision 2004 / 558 / EC) c 0 2
  D  0 0
1 scale: 2, major; 1, minor; 0, negligible
a probability of transmission in a given contact type   
b frequency of infectious contacts of the given type   
c duration of the infectious period
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The within-herd R 0 has been estimated at 4–7 (Hage et al., 1996; 2003). Franken 
(2005) quotes a between-herd R 0 of 5.6 without vaccination, 2.6 with vaccination 
using dead marker vaccine, but only 1.5 with vaccination using live marker vac-
cine. 
EBL
The measures to control EBL, the component(s) of both within-herd and between-
herd R they infl uence and the assessed thrusts are compiled in Table 13.
Table 13 Assessment of EBL control measures using the disease reproduction ratio
  Infl uence on Within Between
Measure component herd1 herds1
Annual BTM surveillance and βa 0 0
health monitoring data cb 2 2
  Dc 1 2
Classifi cation according to decision 426 / 93  β 0 0
of MAF (immediate notifi cation of authorities) c 1 2
  D  1 2
Measures of the circular 2 / 93 of MAF  
 Restrictive measures on farm  
  Culling of the seropositive animals β 0 0
  and serological follow-up of entire herd c 0 0
  D  2 2
 Epidemiological investigation (tracing β 0 0
 of contact herds) c 1 2
  D  0 2
 Program for obtaining and maintaining β 0 0
 the herd disease-free status (biosecurity) c 2 2
  D 0 2
Measures of Decision 98 / 372 / EC (animal health β 0 2
conditions for imports of live bovine animals, c 0 2
“additional guarantees”)  D 0 0
Measures of the decree 6 / EEO / 2004 of MAF β 1 2
and Directive 2003 / 43 / EEC (animal health c 1 2
requirements in respect to bovine semen) D  0 0
Measures of the Decisions 94 / 113 / EC and β 0 1
2005 / 217 / EC (trade and import of bovine c 0 1
embryos) D  0 0
1 scale: 2, major; 1, minor; 0, negligible
a probability of transmission in a given contact type
b frequency of infectious contacts of the given type
c duration of the infectious period
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No numerical estimate for within-herd R 0 is available, but if ingestion of colostrum 
and milk is a major natural route of infection, then the (natural) R 0 is probably not 
much more than the average number of calves an infected cow will have during 
its lifetime. 
MV
The measures to control MV, the component(s) of both within-herd and between-
herd R they infl uence and the assessed thrusts are compiled in Table 14.
Numerical estimates for within fl ock R 0 are unavailable, but if ingestion of colos-
trum and milk is a major route of transmission (Peterhans et al., 2004), then the R 0 
on pasture, just as with EBL, is probably not much more than the average number 
of lambs an infected ewe will have during its lifetime. However, aerosol transmis-
sion of the infection during indoor winter housing (Pålsson, 1976) may be more 
extensive and the R 0 of this type of contact probably would be higher in Finland 
than the former type.
5.2 Summary of the effi cacy of applied measures 
and some further inferences
5.2.1 BVD
The assessments in Table 11 indicate that the measures have a greater potential 
for the prevention of virus spread between than within herds, which makes epi-
demiological sense. Considering the sources of the virus and means of transmis-
sion (Table 3), there is theoretically only one effective within-herd approach, i.e. 
identifying and culling the PI animals, which shortens the infectious period (D). 
The R 0 for acutely-infected animals has been estimated at 2.3 (Cherry et al., 1998), 
but even this is probably a slight overestimate and the infection spreads very slug-
gishly with only transiently infected animals present in the herd (Lindberg and 
Houe, 2005).
The spread of infection between herds takes place mainly through the trade of 
PI animals or dams carrying a PI foetus, through close contact on pastures, and to 
some extent through infected semen or embryo transfer (Table 3). Consequently, 
the effi cient measures include identifying and culling PI animals and strict biose-
curity measures when purchasing (if at all) a pregnant dam that may have sero-
converted during gestation. These measures are able to reduce component β. 
Restrictions on animal movements and biosecurity measures to prevent indirect 
transmission by people are able to reduce component c, and adherence to the ani-
mal health requirement with respect to semen will also have signifi cant potential 
to reduce component c.
Before the laying down of the new decree (MAF 2 / EEO / 2004) the delay between 
actual transmission between herds and suspicion and subsequent detection of a 
67
new PI herd was too long to effectively limit the spread within a herd. The vol-
untary programme launched in 1994 would have provided a tighter schedule for 
the control than the once-a-year BTM surveillance, at least when affi liating to the 
scheme, but unfortunately only a small minority of farmers affi liated to it. For ex-
ample, the number of affi liated farms was 593 in 2001 (MMM, 2002), i.e. 2.8% of 
Table 14 Assessment of MV control measures using the disease reproduction ratio
  Infl uence on Within Between
Measure component herd1 herds1
Annual health monitoring data βa 0 0
  cb 2 2
  Dc 2 2
Classifi cation according to decision 1346 / 1995  β 0 0
of MAF (immediate notifi cation of authorities) c 1 2
  D  1 2
Voluntary control program (1995–2001) and revised   
program compulsory to fl ocks with > 20 ewes, 2001–   
 Continuous (repeated) serological monitoring  β 0 1
 of all animals > 1 year of age c 1 2
  D  2 2
 Biosecurity measures (acquiring of new animals β 0 2
 to fl ock, restrictions on contacts to fl ocks c 0 2
 of lower status, etc) D  0 0
Measures of the decree 15 / EEO / 2001of MAF    
 Restrictive measures on farm
  Restrictions on animal movement β 0 0
  c 1 2
  D  0 2
 Culling of the seropositive animals and their β 0 0
 progeny; serological follow-up of the fl ock c 0 0
  D  2 2
 Epidemiological investigation (tracing β 0 0
 of contact fl ocks) c 1 2
  D  0 2
Measures of Directive 91 / 68 / EEC (animal health β 0 2
conditions in trade of ovine and caprine animals) c 1 2
  D  0 0
Measures of Directive 92 / 65 / EEC (trade in β 0 1
and import to Community of semen of e.g. rams) c 0 1
  D  0 0
1 scale: 2, major; 1, minor; 0, negligible
a probability of transmission in a given contact type      
b frequency of infectious contacts of the given type      
c duration of the infectious period
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the contemporary dairy herds. However, the control efforts in 1994–2003, effective 
between herds (Table 11), did reduce the seroprevalence of both dairy and beef 
BVD herds, and the number of PI herds detected annually (I, II). In fact, fi ve out of 
the seven in 2000, eight out of the nine in 2001 and both of the herds with PI ani-
mals in 2004 were new fi ndings. This indicates that PI herds, once discovered, were 
effi ciently dealt with, but that the infection has not yet been stamped out from 
the population. 
The restrictive measures of the new decree imposed on a suspected or confi rmed 
BVD farm, associated with the epidemiological investigation of the contact farms 
(Table 11), are taken to provide the tools for the fi nal elimination of the infec-
tion within the next few years (II). However, the comprehensive and up-to-date 
information in the Central Bovine Register, Bovine Transfer Register and Animal 
Holding Register could immensely assist the control and eradication efforts, if the 
most could be made of it. The sampling at slaughter targeted at suckler-cow herds, 
which uses data from the Central Bovine Register (Rikula and Joutsenlahti, 2004), 
demonstrates how highly effective a coordinated effort can be. A health-moni-
toring programme for the three-phase calf rearing operations would benefi t not 
only the control of BVD but also that of much more prevalent respiratory infec-
tions caused, for instance, by respiratory syncytial (RS) virus in young stock. Adjust-
ments in the interpretation of screening test results towards higher sensitivity at 
the cost of a lower specifi city would probably also be advisable in the fi nal stages 
of the eradication.
5.2.2 IBR
The assessments in Table 12 indicate that the measures possess more potential to 
prevent the spread between than within herds, rather like in case of BVD. Consider-
ing the sources of the virus and means of transmission (Table 3), there is the or et ic-
ally only one effective within-herd approach, i.e. identifi cation and removal either 
by separation or culling of the seropositive animals, which reduces component D. 
The within herd R 0 has been estimated at about 5 without vaccination (Hage et 
al., 2003; Franken 2005). However, the proportions of seropositive animals in the 
known IBR herds (III, Table 3) do suggest a lower reproduction ratio in the Finnish 
settings.
The spread of infection between herds takes place mainly through the trade of in-
fected animals, contact on pastures, and the use of infected semen and embryos 
(Table 3). Culling or restricting the trade of seropositive animals can reduce the 
probability of transmission (β) through this route. Restrictions on animal move-
ments and biosecurity measures to limit indirect spread can reduce the frequency 
of infectious contacts (component c). Adherence to the animal health requirements 
with respect to semen and embryos can reduce both the probability of transmis-
sion (β) and the frequency of infectious contacts (c).
Annual health moni toring and BTM surveillance, as well as meticulous epidemio-
logical investigation were instrumental in detecting and tracing the IBR-positive 
herds in 1990–1991 (III). Isolation and eventual culling of seropositive and clinically 
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ill animals, both shortening the infectious period (D), were the main measures ap-
plied. Total stamping out of one large herd did of course put an end to this source 
of infection. On-going measures, i.e. continued surveillance, the obligation to im-
mediately notify the authorities, and strict control of animal health both in import-
ing live animals and semen or embryos will be indispensable in limiting the chances 
of re-entry of the virus and preventing wanton spread of the infection.
The fi ve Finnish IBR-positive herds formed three epidemiological units and AI re-
mained the only plausible route of transmission for each unit (III). Only one of the 
herds had purchased an infected animal but the infection had not spread within 
the herd. The effi cacy of transmission – or between-herd R 0 – through AI was es-
timated at a low 1 in 3000 inseminations. However, the low effi cacy may be coun-
tered by the large numbers of inseminations performed annually.
The most obvious risks of (re)introducing IBR into Finland are associated with 
untested semen and embryos, and possibly inadvertent import of (tested) sero-
negative latent carrier animals. It has been considered possible that wild rumi-
nants, especially reindeer (Rangifer tarandus), could be a source of infection for 
cattle. A herpesvirus serologically related to BHV-1 has been isolated from two fe-
male reindeers in Finland (Ek-Kommonen et al., 1986). Furthermore, neutralizing 
antibodies against BHV-1 have also been detected in reindeers (Ek-Kommonen et 
al., 1982; Annual statistics of National Veterinary Institute 1983). However, none of 
the known IBR-positive farms was located in the proper reindeer husbandry area in 
Finnish Lapland, and those dairy herds located in the area have consistently been 
negative in BTM surveillance. Thus, the role of wild ruminants in the epidemiology 
of IBR in Finland remains only a theoretical possibility.
5.2.3 EBL
In keeping with BVD and IBR, the assessed measures (Table 13) have somewhat 
more potential to prevent the spread of BLV infection or EBL between than within 
herds. According to the sources of the virus and means of transmission presented 
in Table 3 there should be two effective measures to prevent both the within-herd 
and between-herd spread: isolation of the seropositive animals from the unin-
fected seronegatives – or preferably culling of the former, biosecurity measures to 
prevent the iatrogenic spread through contaminated needles, and preventing the 
access of herd-mates to the amniotic membranes, fl uids etc. after parturition. Isola-
tion or culling will reduce component D in within-herd spread and component β in 
the between-herd spread, since the spread of infection between herds takes place 
mainly through the trade of animals with PL, and possibly to some extent through 
contaminated semen and embryos. Biosecurity measures effectively reduce compo-
nent c in the spread both between and within herds. Theoretically, heat-treatment 
of the dam’s colostrum and milk or feeding of the offspring only with those from 
seronegative cows in the herd does have a signifi cant potential to limit the spread 
within a herd by reducing both β and c. Transmission by blood-sucking insects is 
most likely only a highly theoretical possibility and measures to prevent it will have 
only a very marginal effect (if any).
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Continued surveillance, immediate notifi cation of authorities, restrictive measures 
on farms and epidemiological investigation to trace the contacts are considered 
elem entary in limiting the spread of the infection between farms in the Finnish set-
ting. In addition to these, adherence to the requirements of animal health both in 
importing live animals and semen or embryos will be invaluable in preventing the 
re-entry of the virus. The risk of (re)introducing EBL to Finnish cattle can theoreti-
cally be associated with import of untested semen and embryos. Iatrogenic import 
across borders via uncleaned needles, surgical appliances or dehorning devices etc. 
is practically impossible. Import of infected but still seronegative animals or illicit 
import of animals with PL must also be considered rather remote possibilities.
5.2.4 MV
The assessments in Table 14 indicate that, as above, the measures have a better 
potential to prevent or limit the spread of infection between fl ocks than within 
them. Considering the sources of the virus and means of transmission (Table 3), 
there are theoretically only a few effective within-fl ock approaches: heat-treating 
the ewes’ milk and bottle-feeding the newborn lambs (reducing β), total separa-
tion of the offspring from infected ewes (reducing c) and culling the infected ani-
mals (reducing D). However, the fi rst two are feasible only as temporary measures, 
for instance, to preserve some valuable genetic stock. Repeated testing of all the 
animals and immediate culling of the seropositives is practically the only effective 
approach within fl ocks.
The spread of infection between fl ocks takes mainly place through the trade of in-
fected animals. Consequently, the effective measures to prevent or limit between-
fl ock spread include immediate culling of seropositive animals and adherence to 
the animal health conditions for intra-Community trade of ovines, which reduce 
the probability of transmission (β). Restrictions on animal movement from infected 
fl ock and other biosecurity measures decrease the frequency of infectious contacts 
(c). Obligation to notify the authorities immediately when the disease is even sus-
pected, and epidemiological investigation to trace the contacts shorten the time to 
trace the infected animals (reducing D).
In Finland, infective contact with other fl ocks, e.g. on pasture or in exhibitions, is 
possible but too infrequent to be epidemiologically signifi cant. Rams that in the 
breeding season visit many fl ocks do have the potential to spread the infection, 
but this is also not known to have happened in Finland. Total stamping out of in-
fected fl ock is certainly even more effective than selective culling in preventing the 
further spread of the infection. The control program requires this if > 10% of the 
animals > 1 year old are seropositive. Seven out of the 14 infected fl ocks revealed 
in the 1994 survey or traced later were eventually stamped out. Six tried the selec-
tive culling and repeated testing approach and three eventually attained an MV-
free (M3) status. Two of the remaining four fl ocks ended sheep production, and 
the other two dropped out of the programme once the restrictive measures were 
withdrawn (V). The importance of epidemiological investigation was clearly dem-
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onstrated: the survey revealed eight of the fourteen fl ocks and the other were 
traced among the contact fl ocks.
After the clearing of the last infected fl ocks in 1998 (V) the infection surfaced 
again four years later (Table 7). This emphasizes the importance of continued moni-
toring of a slow and insidious disease like MV. The epidemiology of the fi ndings 
in 2001 and 2002 is not yet fi rmly established, but preliminary results indicate that 
the animals had had contacts with the known MV-positive fl ocks (V). This accords 
with the observation that the isolated virus strains match with those isolated ear-
lier (Laamanen et al., 2006).
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6 Conclusions
1 The measures applied in Finland largely concur with those listed in the control 
measure Tables 4 and 5, with some minor and one major exception: vaccination 
against either BVD or IBR has never been attempted. The fi nancial compensations 
for the culled animals that the farmers were or are entitled to and the fact that the 
control activities against notifi able diseases are mostly carried out at the govern-
ment’s expense have no doubt eased the compliance with the offi cial control pro-
cedures.
2 Occasional BVDV antibody-positive samples have been recorded in the annual 
statistics of the National Veterinary Institute since 1965. The Finnish approach of 
moni toring the BVD antibody status of a large majority of all cattle herds and sys-
tematically tracing and eliminating the animals persistently infected with BVDV 
was successful in reducing the seroprevalence of the infection to less than a third 
of what it was when the voluntary control programme was started in 1994, and 
even further in respect to PI herds. However, decisive progress to complete eradica-
tion will require the instruments of the new decree, in effect since May 2004. 
3 It appears that IBR or BHV-1 was introduced into Finland in 1968 when import-
ing a live AI bull to a station. The infection is considered to have spread via infected 
semen to a number of herds, estimated at less than 10. The large-scale BTM surveil-
lances in 1990–91 revealed three IBR herds and meticulous tracing of their contact 
herds and testing all of the animals in them detected two further herds. Culling of 
the seropositive animals from the herds, restrictive measures on their animal trade 
and subsequent serological follow-up, and total stamping-out of one herd were 
suffi cient in eradicating the infection from Finland without the need to resort to 
the use of vaccines. Continued surveillance and the obligation to notify authori-
ties immediately will guard against unchecked spread in the case of re-entry of the 
infection.
4 The database of haematological and later serological health moni toring re-
sults show that EBL was introduced into the country probably before the 1960s. 
Between 1966 and 1997, positive results were recorded annually in the statistics 
of the National Veterinary Institute. Culling of the seropositive animals from the 
herds and restrictive measures on their animal trade were essential and suffi cient 
measures to eradicate this infection. Continued surveillance, strict examination of 
suspicious pathological or meat inspection samples and the obligation to immedi-
ately notify authorities will safeguard the present disease-free situation. 
5 It is probable that MV was fi rst introduced into Finland in 1981 in imported 
sheep. The infection was not detected between 1982 and 1993 according to the 
annual statistics of the National Veterinary Institute, until a large-scale survey in 
1994 and subsequent investigation revealed that the infection had insidiously al-
ready spread to 14 fl ocks. The stamping out of entire fl ocks in several cases, cull-
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ing of seropositive animals and their progeny, scheduled serological testing and 
restrictive measures on farms were suffi cient to reduce the occurrence to an un-
detectable level. However, the two positive serological fi ndings in surveys carried 
out in 2001–2002 demonstrate that the sporadic occurrence of MV is still possible.
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